

SARS-CoV-2 and the Vaccination Hype

Piero Sangaletti¹, Jane Doe², Antonietta Gatti³, Clemens Arvay⁴, Livio Giuliani⁵, and Herbert Lettner⁶

¹Edge-Institute Austria at ER-System Mechatronics, Golling, Austria: abocs@protonmail.ch

²ABoCS (Advisory Board of Concerned Scientists), Tampa, Florida USA

³Cofounder and Principal Investigator of Nanodiagnostics, SRL (Società a Responsabilità Limitata), Italy

⁴Independent scientist and textbook author in Health Ecology, Vienna and Graz, Austria

⁵International Commission for Electromagnetic Safety (ICEMS), Rome, Italy; and

⁶Department of Chemistry and Physics of Materials, University of Salzburg, Salzburg, Austria.

ABSTRACT

The engineered spike protein of SARS-COV-2 and the corresponding infectious disease COVID-19 attributed to it hold in their grip on a large portion of humanity. The global race for a counter strategy quickly turned into a search for a vaccine as the preferred means to contain the virus. An unusually rapid development of different and completely new classes of experimental therapies that would widely be referred to as “vaccines” raised questions about safety, especially with regard to emergency use approval (EUA) being granted with unprecedented urgency and hardly any critical scrutiny. At present, independent researchers, even some former proponents and insiders, of the currently ongoing global experiment represented as a “vaccination” campaign point primarily to the lack of public safety studies based on empirical datasets that should be obtainable for the tens of millions, even hundreds of millions, of doses of mRNA and DNA vector therapeutics being distributed as “vaccines”. Studies regarding efficacy and “side effects” (sometimes fatalities or permanent iatrogenic injuries) of these experimental therapies have been by-passed in favor of short-term field data from real patients which inevitably raises scientific and ethical questions particularly in view of the fact that the persons and entities responsible for public safety hold deep financial and other vested interests in speeding along the distribution of the experimental pharmaceutical products. The lack of an open discussion about the experimental therapies for COVID-19 now being applied across all age groups, even children hardly impacted by COVID-19, is worrying. The core principle of open debate without pre-conceptions or vested interests in outcomes has been and continues to be utterly ignored. We hope to engage scientific discussion with the hope of helping decision-makers, the general public, and the media alike to consider the subject-matter of what is at stake in a context of reason rather than panic.

Keywords: *COVID-19 vaccination, quasi-species consortia, mRNA-/vector-vaccine, SARS-CoV-2*

1. Introduction

Within a short time after the emergence over a year ago in China of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its subsequent spread as COVID-19, the alleged global “pandemic” that followed supposedly caused more than 304 million infections with 5.5 million deaths also attributed to the virus (Gardner et al., 2021 as of December 2021). The disease statistics revised hour by hour were all the while being “confirmed” by health officials using more than 30 cycles of polymerase chain reaction (PCR) testing in a manner guaranteed to produce a huge number of false positive COVID-19 cases as shown by Kucirka et al., (2020) and Watson et al., (2020). Nevertheless, the US Centers for Disease Control and Prevention (CDC) has continued up to the present time to use up to 45 amplification cycles of PCR to diagnose hundreds of thousands of “cases” of “COVID infections” in spite of the fact that the inventor of the PCR procedure himself, Kary Mullis (1986), insisted that PCR was and is inappropriate for diagnosing *any disease whatsoever* (see video clip BL, 2020). An observation in line with Chang et al., (2020) who likewise pointed out that there is a lack of a clear-cut “gold-standard” for COVID-19 testing. A more reliable diagnostic method for direct demonstration of coronavirus antigens in nasopharyngeal aspirates or swabs makes use of monoclonal antibodies (White & Fenner, 1994). Given the drawback that coronaviruses are difficult to grow in vitro, isolation from diploid fibroblast cell lines also provides reliable results (Burrell et al., 2016). Moreover, deaths were often attributed to COVID-19 as decreed after the fact by some health official without the deceased ever having manifested symptoms or having been certified as infected with SARS-CoV-2. For documentation, (O’Looney, 2021; Loffredo, 2021; Kennedy, 2021, p. 772). To our knowledge, exceedingly few of the deaths attributed to COVID-19 were ever verified by the gold-standard of a careful autopsy, and none of the deaths dealt with personally by John O’Looney were autopsied. None of the persons he dealt with ever showed symptoms of COVID-19 nor were they ever diagnosed as having contracted it while they were still living according to their family members. Nonetheless, COVID-19 was registered as the cause of death by health officials.

1.1 Media Attention

In the hype of media attention that followed the first reported infections and deaths, and particularly after the lockdown impacting the developed nations world-wide in March 2020, it was hardly clear whether any particular death attributed to COVID-19 was of an individual who died after being designated as a “case” infected by SARS-CoV-2, or whether the deceased person was actually killed by the virus (Madl et al., 2021). In the meantime, a frantic search for a quick fix was launched at the expense of taxpayers, which search — a few months later — resulted in several candidate “vaccines” being released by emergency use authorization (EUA).¹ To understand the “patho-physiology” of this novel disease, dubbed COVID-19, in the days and weeks following the outbreak, it became known that the new virus (in several variants) interferes in manifold ways with the host genome. For the details, readers are referred to Fleming (2021). He documents and cites (1) the long public record of research findings reported in prestigious scientific journals, (2) the stream of lucrative patents for virus components and the like, and (3) the series of government grants for millions of dollars in a little more than 141 pages showing how SARS-CoV-2 was manipulated over several years, even decades, leading up to the “pandemic” that would become known as COVID-19. The genomic interference attributed to the virus, or more correctly according to Fleming, caused by its genetically engineered spike protein (see our Figure 1) triggers what Blaylock (2021) has termed a cytokine storm, and which according to Dotan et al. (2021) is also associated with a host of distinct antibodies as well as autoimmune diseases. Due to its molecular mimicry of human sequences, the spike protein of SARS-CoV-2 readily binds with the membrane based ACE2 (angiotensin converting enzyme 2) receptors (Guzik et al., 2020; South et al., 2020)

¹ On Dec. 9th, EUA-status for Comirnaty has been amended by the US-FDA; <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17>.

present in various cell types found in the human lungs, heart, blood vessels, kidneys, liver, testes, and gastrointestinal tract (Figure 1).




Figure 1. Visualization of SARS-CoV-2 (center) with its ultrastructural morphology. Grouped around the virus appear autoantibodies (left) and autoimmune diseases (right) both linked to the SARS-CoV-2-infection (modified after Dotan et al., 2021), but may also be relevant for the associated “side effects” of the experimental therapies now being represented to the public as “vaccines”. Note that the specific named diseases and corresponding auto-antibodies are not actually associated with the particular locations on the SARS-CoV-2 virus suggested in this artwork, but are nonetheless well-attested in relevant research.

As highlighted below, the widespread presence of the ACE2 receptor within the human body makes those cells likely targets of opportunity for potential adverse effects following vaccination. In the majority of cases, a COVID-19 infection passes rather quickly with hardly any noteworthy symptoms. However, in a small percentage of cases, the infected persons report body aches with fever and other flu-like symptoms. But severe cases are relatively rare and deaths unambiguously attributable to SARS-CoV-2, account for only about 6% of the total number of COVID-19 deaths reported by the CDC — numbers, as already noted, greatly inflated by a huge percentage of the “cases” falsely diagnosed as positive for COVID infection by the inappropriate use of PCR tests with an absurdly high number of cycles (see the Fleming, 2021 reference cited above). Even so, 94% of the observed fatalities originally attributed to COVID infection, as admitted by the CDC (2020), involved one or more co-morbid disease conditions that could not be excluded as the proximate cause, of the death in question. Autopsies performed on hospitalized COVID-19 patients that did not recover revealed conditions such as respiratory failure associated with diffuse alveolar damage, and/or multiple-organ failure, cardiac decompensation, complication due to malignant tumors, septic shock, and various other chronic disease conditions and serious disorders. The commonly associated risk factors for severe life-threatening SARS-CoV-2 infections included a litany of life-style-issues such as obesity and hypertension, as well as serious disease conditions such as tumors and diabetes mellitus, or the patients who died were advanced in years with overall poor health. In many instances fatalities involved people who were, already, nearing the end of their lives before the onset of the COVID-19 “pandemic” attributed to SARS-CoV-2.

1.2 A Common Dysfunction in Recipients of the Experimental Injections

One common injury attributed to the virus in its various forms was vascular dysfunction with altered endothelial metabolism not only in the lungs but in almost any organ that was closely examined in the severely ill or deceased persons (Haberecker et al., 2021). Given that patients with pre-existing endothelial dysfunction already have a suppressed capacity to restore injured vasculature and are already inhibited by micro-thrombosis, they are particularly vulnerable to the impact of any variant of SARS-CoV-2.

With all this in mind, it seems stranger than ever that the current spectrum of mRNA and genome vectoring “vaccines” have been granted emergency release at all. Bearing in mind that the therapies in question (see further explanation in reference to our Figure 2 below on page 180) are radically different from traditional vaccines insofar as these new experimental therapies aim to control certain genetic processes formerly, but now no longer, out of the reach of medical interventions. For that reason, in this paper we refer to any of the experimental COVID-19 injections as a “disease component replicating therapy”, or a “DiCoReTh-injection” for short. As will be shown later, the associated “side effects” — unintended iatrogenic consequences consisting of injuries of various sorts, some of which are already occurring and others that are known to be possible, even likely, downstream — of these novel classes of experimental genetic therapies logically must interact negatively with the comorbidities that evidently have actually led to some severe or even fatal infections by SARS-CoV-2. One of the prominent and obvious dangers, known to those examining the research on DiCoReTh-injections, is that the genome interference brought into hundreds of millions of people by these experimental injections are virtually certain to aggravate any existing distressed endothelial metabolism causing, among other undesirable effects, micro-thrombosis (McCullough et al., 2021). Personal accounts of adverse effects in an oral history format can be accessed via the testimonials project (Livny, 2021).

2.0 The Normal Human Virus Sphere Disrupted?

Viruses are believed to be essential and dominant players in microbial ecology (Moelling, 2017), and yet fairly little is known about the patho-physiology of those that can cause disease, their relevant threshold levels, their possible sources (means of transmission), and modes of transformation. The family of single stranded RNA (ssRNA) viruses — to which SARS-CoV-2 belongs — has peculiar properties as it has enormous genomic flexibility, on the one hand and species-specific persistence, on the other. These viruses, as a result, have genetic stability in their own right and at the same time can co-evolve along with changes occurring in their host cells including the manufacture of antibodies against the viruses by the host. Under laboratory conditions, these viruses generate different gene populations in rather short periods of time. However, under natural conditions, without the kinds of artificial disturbances as ordinary vaccine injections produce, viruses themselves tend to maintain significant homogeneity resulting in molecular clocks that run much more slowly than those that seem to be in play with the so-called “acute viruses” (Villarreal, 2005) which change more quickly. In the case of SARS-CoV-2, Fleming (2021) documents published research showing how this particular virus was targeted by “Gain-of-Function research and thus pre-designed for very rapid changes enabling its downstream variants to adapt at Warp Speed to changing conditions in the host population. Given that hundreds of millions of humans have already been impacted by injections containing the genetic vectoring to generate countless copies of the mutating spike protein itself, SARS-CoV-2 is, it seems, assured of rapid and constant mutation. All this is confirmed by genetic analyses performed six months after the infected persons studied were diagnosed. Results showed dramatic genetic modifications in the novel “mutated” genome compared to its original sequence. The most prominent alterations were in the spike-protein itself at D614G (Zhang et al, 2020a), E484K (Wise, 2021), B.1.1.7 (Rambaut et al., 2020), B.1.351 (Lessells, 2021). Some of the variants found already observed, but new

variants were appearing continuously all the while that such analyses of the SARS-CoV-2 variants were being done (CDC, 2021a; ECDC, 2021, Tablizo et al., 2021).

2.1 Quasi-Species Consortia (qS-c)

While mutations are one concern, quasi-Species consortia (qS-c) — quite analogous to quorum sensing in bacteria (Miller and Bassler 2001, Waters and Bassler 2005) — represent another means by which the virus can adapt and increase its own infectivity in hosts. Behavioral motifs of cooperative RNA-agents are the drivers behind the basic viral skills required to invade and infect hosts and which are responsible for the synthesis of *de novo* nucleotide sequences in the host's genomic economy. Changes in the host's genetic material can come about by the virus effecting an insertion, substitution, or deletion in native host sequences (Villarreal and Witzany, 2013; Villarreal, 2015). This means that for every variant (1) a given nucleic acid sequence does not maintain a unique position, but rather depends on its context of use; which in turn implies that (2) the nucleotide sequences follow real-life conditions that aren't randomly arranged. The far-reaching effects of such variations as observed under laboratory conditions are much broader: qS-c (1) concur in related populations and exclude relatives; (2) possess minority populations that are essential for overall fitness; (3) exhibit heterogeneity which is important for fitness but is not observed in the consensus type; (4) are able to repress their own replication through lethal defects; and (5) are composed of members that interfere with the replication of the collective. Hence, qS-c populations are highly diverse, and it is assumed that no two genomes therein are identical — even if a cloned genetically homogeneous template is used to trigger a cycle of infection (Villarreal and Witzany, 2013; 2021), it will not *remain* identical to its own starting sequence. This fact is relevant to the ongoing “pandemic” and the EUA “DiCoReTh-injections” that are claimed to have the power to stop it. The fact that a non-negligible number of people continue to test positive for COVID-19 long after the infection, and all the symptoms formerly prominent, are gone, suggests that the specific RNAs of SARS-CoV-2 can be and are being reverse-transcribed into human cells (Zhang et al 2020b; Desfarges & Ciuffi, 2012; Villarreal & Witzany, 2021). In patients recovered from Long-COVID-19 (Raveendran et al., 2021), an unusually elevated concentration of “G-protein coupled receptors” tied to “functional autoantibodies” (GPCR- τ AABs) have been detected in their serum. Associated symptoms included alopecia, fatigue, tachycardia, bradycardia, and myocarditis among others (Wallukat et al 2021). So far, only a few cases are available showing host-virus chimeric reads in RNA-sequencing data from SARS-CoV-2 infected cells and samples from COVID-19 patients that would suggest viral integration into the human genome (Yan et al., 2021). Hence, only follow-up studies of Long-COVID cases will show whether this can be determined for sure (Lopez-Leon et al., 2021).

2.2 Cells and Tissues Known to Be Impacted

There is a third concern for human endogenous retroviruses (HERV) fulfilling crucial life functions (Villarreal, 2005) — in particular non-coding retroviral RNA sequences within the human genome are responsible for editing tasks. Phylo-ontogenetically speaking, this feature accounts for crucial competencies such as the production of “replicase, polymerase, integrase, DNA-repairs, restriction/modifications of gene expression, methylation, the eukaryotic nucleus, the division of transcription and translation, the creation of nuclear pores, tubulin-based chromosome duplication, empowering of the innate immune system, the adaptive immune system, health in cartilage, bones, skin, mucus, milk, the placenta, viviparity just to name a few (Witzany, 2006). Why does this matter? Because at least two of the ongoing DiCoReTh-injection platforms use RNA and DNA technology (Lurie et al., 2020) and according to Lyons-Weiler (2020) reveal immunogenic epitope similarities of SARS-CoV-2 with homologues to human proteins. Adiguzel (2021) drew attention to residual alignments to SARS-CoV-2 peptide with almost a dozen known human proteins. Moreover, over-expression of the spike protein significantly suppresses both homologous recombination and non-homologous end joining (Jiang & Mei, 2021), processes that are essential for DNA repair in cells.

Autoimmune reactivity in response to viral antigens following infection or vaccination can easily be derived from cross-reaction with human tissue antigens that share sequence homology with the virus; this includes cells in the heart muscle, skeletal muscles, thyroid gland, kidneys, brain, pituitary gland, testes, lung, blood, gastrointestinal tract, eye, liver, bone marrow, adipose tissue, skin, and many ubiquitous proteins (Vojdani et al., 2021). The major autoimmune findings related to SARS-CoV-2 regard anti-phospholipid, anti-nuclear, p- & c-anti-neutrophil cytoplasmics, anti-cyclic citrullinated peptides, and anti-gangliosides GD1b antibodies (Salle, 2021). Given that the viral spike protein is a potential epitopic target for biomimicry-induced autoimmunological processes it will be extremely important to see if GPCR- ϵ AABs will also become detectable after vaccination against the virus (Wallukat et al 2021).

3.0 The Novel Class of “DiCoReTh-Injections”

About a third of the potentially targeted human proteins (putative autoantigens) are key players in the adaptive immune system. Thus, a gene-based-therapy by any “DiCoReTh-injection” could generate a series of side effects. Specifically, binding antibodies that do not neutralize themselves but only bind to the surface of the virus-infected cell, may render the viral particle invisible to the immune system. Practically speaking, such a “stealth” mode can amplify viral replication, and, in that way can make subsequent infections more severe — an effect known as antibody-dependent enhancement (ADE). Such an effect depends on how antibodies target different epitopes of the S-protein (Iwasaki & Yang, 2020). Indeed, ADE was observed almost two decades ago when SARS and MERS first became known (Lee et al., 2020). It has been documented to occur through two distinct processes in viral infections: for one, enhanced antibody-mediated uptake into Fc gamma receptor IIa (Fc γ RIIa) expressing phagocytic cells can lead to increased viral infection and replication, or, for the other, by excessive antibody Fc-mediated effector functions or immune complex formation causing enhanced inflammation and thus immunopathology. Both ADE pathways can occur when non-neutralizing antibodies, or antibodies at sub-neutralizing levels, bind to viral antigens without blocking or clearing them to prevent any infection (again, see Lee et al., 2020). ADE is marked symptomatically by the fact a secondary infection is more severe than the primary infection was (Grenfell et al., 2004). As a result, ADE affects safety and efficacy of passive and active immunization schedules (Negro, 2020; Xu et al., 2021). To reduce the risk of such pathogenic priming, all the parts of the epitopes that are homologous to human proteins ought to be excluded from any candidate DiCoReTh-injection/genetic therapies (Cappello et al., 2020). Yet, all DiCoReTh-injections target human protein biosynthesis aiming to manipulate the RNA translation at the ribosome level in order to induce the production of viral proteins as antigens, usually spike proteins — see also the “vaccine” package leaflet (WHO, 2021; EMA, 2021c,d,e,f). In addition, the allergenic potential of novel adjuvants such as PEG and polysorbate (Garçon et al., 2012; Wang et al., 2010), also commonly referred to as excipients and which are present in DNA vector therapies as well as the mRNA DiCoReTh-injections. Furthermore, the lipid nanoparticles encapsulating mRNA components of the Pfizer and Moderna DiCoReTh-injections may contain conjugated adjuvants or may themselves act as “adjuvants” (Chung et al., 2020; Kim et al., 2021; Zhang & Xia, 2021) — all of this making iatrogenic injuries even more probable (Coors et al., 2005; Jackson et al., 2020; Cabanillas et al., 2020; deVrieze, 2021; Kim et al., 2021; Kostoff et al., 2021). For example, Pujol et al. (2021) report on three cases of thyroiditis which they diagnose as adjuvant induced acute inflammation (ASIA) “induced by the mRNA-based SARS-CoV-2 vaccination”. With such warning signals in mind, DiCoReTh-injections with the EUA designation already granted: i) should not be deemed to have established a standard of prevention in the settings where they are being introduced (Singh & Upshur, 2020); ii) should require that unresolved safety concerns be properly addressed (Bruno et al., 2021); and iii) should be used only after conventional therapies have been exhausted (Shi, 2020; Inserra et al., 2021; de Melo et al., 2021; McCullough et al., 2021; SWPRS, 2021; Nair et al., 2021). In other words, EUA experimental therapies such as the genetic “DiCoReTh-injections” addressing the COVID-19 “pandemic”

should only be used if less invasive conventional therapies have failed (Janiaud, et al, 2021; McCullough et al., 2021).²

3.1 A “Trojan Horse” Effect?

Although the evidence is limited, it appears already that the implementation of “genetically modified” so-called “vaccines” — actually experimental genetic therapies — may interfere with the target cell’s genome leading to the activation of oncogenes and/or deactivation of anticarcinogenic gene sequences, thus increasing cancer risks (Ura et al., 2014; Hasson et al., 2015; Aubrit et al, 2015). However, the few studies available underline the likelihood of the actual integration of the components of these “vaccines” into the human genome. Such incorporations into a person’s DNA may occur owing to i) viral mRNA and adenovirus vector DNA (Doerfler, 2021) with epigenetic consequences yet to be determined; ii) SARS-COV-2 infections whereby copies of viral subgenomic RNAs may integrate into the DNA of the host cell via reverse transcription — the latter being a suspected cause for symptomatic infections long after the symptoms and evidence of initial infection have cleared (Zhang et al., 2021).

Such an undesirable “Trojan Horse” effect is likely if the transferred nucleic acids designed to mimic human genes are actually integrated into human protein biosynthesis (Chiu et al., 2021; Mansuriya & Altintas, 2021; Xu et al., 2021). Independent researchers examining genetic DiCoReTh-injections, therefore, point out that any short-cuts to clinical evaluations for the development of experimental injections against COVID-19, especially when based on the transduction of nucleic acids (themselves capable of unknown adjuvant-type “side-effects” such as thyroiditis; Pujol et al., 2021), would be a violation of the precautionary principle (Jiang, 2020; Arvay, 2020; Rosenthal and Cummings, 2021). In the long run, and as seen with SARS almost a decade ago, it is shocking, even potentially horrifying, to consider how the novel DiCoReTh-injections introduced into hundreds of millions of people may, over the coming weeks, months, and years, alter specific functions of the human body, especially by damaging the immune system. Autoimmune diseases such as Guillain-Barré Syndrome (Shao et al., 2021), autoimmune induced hepatitis (Avci & Abasiyanik, 2021), and acute autoimmune transverse myelitis (Hirosae et al., 2021) along with a wider spectrum of autoimmune phenomena (Chen et al., 2021) have been attributed to the novel DiCoReTh-injections. Evidence is even mounting that repeated vaccinations with the same antigen at short intervals (“booster shots”) destabilise the immune system so that autoimmune processes are triggered (Tsumiyama et al., 2009) and in some cases are lethal (Shimoyama et al., 2021).

None of the foregoing outcomes should be surprising given the tumorigenicity of cell substrates used in the production of the constituents of the DiCoReTh-injections which may include the use of tumor allografts, transfer of known or unknown viruses, and the intentional incorporation of oncogenic agents or cell components that may produce *de novo* or re-ignite existing cancerous cells (Aubrit 2015; Arvay, 2020; Sumi et al., 2021; Goldman et al., 2021; VAERS, 2021³). Grave adverse potentials arise as the source material for the manufacture of DiCoReTh-injections rely on animal cell lines *in-vitro*. Combined with the fact that modified “designer cell lines” — derived from duck, monkey, and dog tissues, as well as human embryonic kidney cells, known under brand names like EB66®, AGE1.CR®, PER.C6®, HEK 293, etc.— are being used for

² It was after a year of crisis management with emergency-approved vaccines although the EU would finally come back to conventional therapies of which five seemed to get clearance (EC, 2021a).

³ VAERS-ID examples of tumor triggers and tumor progression after injection: 1027247, 1039221, 1046027, 1066305, 1073882, 1096952, 1124577, 1103186, 1470499, 1471305, 1478347, 1485987, 1486583, 1538755, 1558249, 1587116, 1582941, 1623680, 1641095, 1646951, 1647170, 1647308, 1651636, 1664657, 1664813, 1665051, 1666115, 1669875, 1684985, 1685076, 1697379, 1714282, 1714343, and 1997540.

the production of novel influenza vaccines along with the new DiCoReTh-injections not only raises ethical questions, but could open a Pandora’s box inside human cells (Hsee and Ruan, 2016).

3.2 One or More Self-Replicating Disease Components?

The currently most popular DiCoReTh-injection platforms opted to include RNA-, DNA-, vector-, inactivated, live attenuated-, and protein-subunit-“vaccines” (Ng et al., 2020). So far, RNA and vector “vaccines” have been given priority for widespread use in the general public — see Figure 2; for regular updates on their distribution see Mathieu et al. (2021). Yet these experimental “DiCoReTh-injections” are not without known risks. As nanotechnology drugs, which in their essence are gene-therapies they aim to cause host cells to produce the “exogenous” active viral component — a disease agent or component of the suspected cause of disease. As mRNA-based DiCoReTh-injections contain the spike glycoprotein (S) of SARS-CoV-2 encapsulated in lipid nanoparticles (LNPs) (EMA, 2021c), <https://webmail.sbg.ac.at/owa/redir.aspx?REF=jtGS4Wlh0-hTk9yBMDykcfc45ENXSa-I6Lpn1kdc4ecohFUC3GxvZCAFodHRwczovL3d3dy5lbWEuZXVyb3BhLmVlL2VuL2RvY3VtZW50cy9hc3Nlc3NtZW50LXJlcG9ydC9jb21pcm5hdHktZXBhcilwdWJsaWMtYXNzZXNzbWVudC1yZXBvcnRfZW4ucGRmKS4lMjBUaGU>.the encapsulation itself being an adjuvant (Chung et al., 2020; Kim et al., 2021; Zhang & Xia, 2021) represents an intentional “Trojan horse” that can by-pass the sensors on the cell membrane and can enter the sacrosanct region of the nucleus and nucleolus undetected. There it can set up shop as a manufacturer of whatever variants of the disease component it may already be programmed to construct, or that may arise based on modifications of the genome of the disease component that may occur after the DiCoReTh-injection has done its preliminary work. The design is such that the liposomes won’t activate an immediate defensive response. While pure RNA sections are instantaneously recognized and upon entrance into the cell become neutralized, an LNP is easily phagocytized and penetrates the cytoplasm where the external lipid membrane is degraded releasing the glycoprotein load.




Figure 2. Traditional intramuscular injection of viral proteins (left); RNA injection designed to enable the cell to produce the active component of the “vaccine” itself (center); and vector introduced via gene shuttle also aiming to produce the active “vaccine” component (right). The dashed lines represent the hypothetical case where the injected RNA is reverse transcribed or the DNA becomes persistently integrated into the host cell genome. Collectively, the models in the middle and at the right of the figure represent the intended working of what we are calling “DiCoReTh-injections”.

The use of vector DiCoReTh-injections involves recombinant adenovirus type-5 (Ad5) vectors that have already been found to be problematic in studies associated with HIV. Participants involved in such studies,

after being artificially infected with the adenovirus, tested positive and as such were at elevated risk of HIV-1 infection (Buchbinder et al., 2020).

3.3 Emergency Use Authorization for Half-Baked Ideas?

Up until the COVID-19 crisis, no mRNA drug or DiCoReTh-injection had been licensed for use in humans. There was a feasibility study with an RNA-DiCoReTh-injection several years ago (Bahl et al., 2017), but given that the technology is still in its “infancy”, it is not surprising that it is exceedingly difficult to get RNA into cells without triggering serious side effects (NatBiotech, 2016). On theoretical grounds, based on many different disease conditions, Oller and Shaw (2019) showed how any penetration into the nucleus, particularly the nucleolus where the main cache of DNA is stored and normally well-protected against toxicants and other invasive factors, appears to be essential to the initiation of metastatic cancers. How can vector-based therapies, posing now more or less as traditional vaccines, be optimized to avoid unintended RNA-splicing reactions? How can we be assured of the safety of pharmaceutical products that deliberately breach the most intensive biological barriers of the body (Kowarz et al., 2021)? Currently, we cannot rule out the possibility that the spike open-reading frame of SARS-CoV-2 can be disrupted by arbitrary (unpredictable) splicing events when transcribed inside the nucleus, possibly leading to soluble spike protein variants. The protein content roughly consists of about 2/3 of human and 1/3 of viral origin, together accounting for about 1,000 different proteins present in a vector DiCoReTh-injection. This also includes protein impurities that contribute to the strong clinical reactions with flu-like symptoms that are often observed following vaccination (Krutzke et al., 2021). For compositional analysis of mRNA and vector therapies represented as “vaccines”, see Seneff and Nigh (2021) and also Broudy and Kyrie (2021).

Both approaches raise ethical concerns as they purport to reduce the living languages of the genome to a computer-like operating system, supposedly making the “software” of life fully accessible to genetic engineers. Based on current knowledge, these novel DiCoReTh-injections urgently need further research as so-called “chromosomal insertions” are known to happen to a certain extent, and can have undesirable effects (Baum et al., 2006).⁴

4.0 An Unending Series of Shots and Booster-Boosters?

With these considerations in mind, any efforts to tame or even eliminate (zero-COVID approach) the spread of SARS-CoV-2 viruses via novel biotechnological tools is an impossible goal to achieve. And even if it could be achieved, COVID-19 immunity could be lost within months (Seow et al., 2020), making frequent booster shots an inevitable routine, while at the same time demonstrating the lack of coverage or power of the prior shots against a rapidly diversifying set of moving targets (Ou et al., 2021; Pachetti et al., 2020). Will any number of boosters be more effective than the ones already currently being deployed? Experience from the past has already made it evident that recipients of trivalent inactivated influenza vaccines (TIV) had an increased risk (4.40) of virologically confirmed non-influenza infections (Cowling et al 2012), and, though denied by researchers, a surprisingly high rate of interference with embryological development resulting in

⁴ The term “undesirable effects” falls somewhat short. From a holistic therapeutic approach, we are inclined to say that such insertions will ultimately disrupt the natural harmonic gene-sequence pattern, thus interfering with self-similar properties within the genome. Once this fractal pattern is altered, the harmonically interwoven life-processes of the organism as a whole are altered. In cases of some almost negligible modifications, we may expect disease predispositions, whereas in more consequential ones, aggressive forms of chronic pathologies eventually resulting in premature death are to be expected. In terms of signalling requirements, such insertions can detune the finely articulated resonance patterns across the organism just as a detuned radio-receiver that is not perfectly aligned to the transmission frequency can generate blurs, cracks, ditches, and interference thereby rendering the melody and its message uninterpretable.

congenital defects or fatality to the unborn (Eaton et al., 2018). Especially for non-influenza viruses, the chances to find both coronavirus and human meta-pneumovirus among vaccinated subjects were significantly higher (OR = 1.36 and 1.51, respectively) than in unvaccinated individuals (Wolff, 2020). Candidates against the feline coronavirus FIPV (passive vaccination) led to adverse effects with the consequence that vaccinated cats showed an increased risk of a symptomatic infection compared with cats that didn't receive the vaccine (Takano et al., 2019).




Figure 3. Estimation of the effectiveness of vaccination against influenza A(H1N1) and influenza A(H3N2) in three age groups during the 2018/19 season, based on a point estimate and a 95% confidence interval. The arrowheads indicate a value beyond the Y-axis shown. FRG (◇), DK (○), UK (□), EU (△); (composite figure based on data from Kissling et al. (2019) and Buda et al. (2019)).

4.1 Is the Notorious Inefficacy of Influenza Vaccines Relevant?

This immediately raises the question of vaccination efficiency (VE), which often is found to be age-dependent. Data on VE are rather scarce — the data available, however, report age-dependent VE against laboratory-confirmed influenza A(H1N1) for Denmark and the UK (Kissling et al., 2019). A similar age-dependent trend in VE of laboratory confirmed A(H1N1) and A(H3N2) influenza cases was also documented in Germany — there, the negative VE values for some age-groups are even more striking (Buda et al., 2019). Figure 3 depicts such an exemplary trend. A negative VE-value implies that no statistically significant protection of the vaccinated individual against influenza can be demonstrated compared to unvaccinated people; i.e. in other words, a vaccinated person has a higher risk of contracting influenza at the same exposure conditions than an unvaccinated individual. Indeed, recent data analysis regarding DiCoReTh seem to reveal exactly that trend; i.e. that VE against the most recent strains is fading steadily. In the age groups between 15-24, VE plummets into negative territory even after the 2nd dose (especially for vector-“vaccines”, somewhat less for mRNA “vaccines”) making repeated booster doses a necessity (see table 2 of Andrews et al., 2021).

4.2 VAERS and the Death Toll of DiCoReTh-Injections

A similar relationship exists for other traditional vaccines. In the case of polio vaccines, for example, it has been observed that vaccination campaigns triggered polio incidence in regions where the virus was endemic (wild poliovirus, WPV), while in regions with non-endemic polio, as a result of vaccination there were vaccine-derived poliovirus cases, cVDPV that would actually increase steadily over the following years (Jenkins et al., 2010; PGEI, 2021). Paradoxically, as we aim to move toward global polio eradication, the burden of vaccine-induced polio is becoming increasingly important (Lopalco, 2017, Leslie, 2021).




Figure 4a. Top: Cumulative reports of Vaccine Mortality Rate per year. The period of the COVID-19 DiCoReTh-injection introduction reflects data only till December 24th 2021 (VAERS, 2021).

Figure 4b. Bottom: Graph showing the pooled weekly total number of deaths provided by the 29 European states⁵ contributing to the EuroMomo registry database within the age group 15-44 years over the last four years. The greyish area designates the normal fluctuations (± 2 z-score units), whereas the dashed red line (z-score of 4) equated to about 200 excess deaths per week while a score of 6 equates to 300 excess deaths (above the baseline). Observed peaks at the turn from one year to the subsequent year are attributable to the annual appearance of the flu-season. In 2020/21, that season was regarded as insignificant (GISRS, 2021), leaving the subsequent rise in registered death cases (denoted by the encircled area) as attributable most probably to the enforced DeCoReTh campaign (EuroMomo, 2022).

⁵ Austria, Belgium, Cyprus, Denmark, Estonia, Finland, France, Germany (Berlin), Germany (Hesse), Greece, Hungary, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovenia, Spain, Switzerland, UK (England), UK (Northern Ireland), UK (Scotland), UK (Wales), and Ukraine.

4.3 DiCoReTh-Injection Recipients at Greater Risk of COVID Infection?

In spite of the size of the ongoing experiment, with tens, even hundreds of millions, being injected during the world-wide SARS-CoV-2 vaccination campaign, it seems — as stressed in Figure 4a and 4b — that the novel line of vector-DiCoReTh-injections is resulting in markedly higher fatality rates not only among the elderly but across the broad spectrum of persons already being exposed (Figure 4a) and in the last eight weeks of 2021 was impacting — all this in contrast to traditional vaccines, especially, the conventional influenza vaccines (EudraVigilance, 2021; VAERS, 2021).⁶ While the efficacy of the current vector-DiCoReTh-injections is still being evaluated (i.e. initially, a relative risk reduction to contract COVID-19 of $\approx 95\%$ for the mRNA DiCoReTh-injections and $\approx 67\%$ for vector DiCoReTh-injections, which translates to an absolute risk reduction of only $\approx 0.84\text{--}1.2\%$ and 1.3% respectively (Olliaro et al., 2021), a significant drop in efficiency is already observable (Wadman, 2021; Uriu et al., 2021; Keehner et al., 2021). With the emergence of the “delta” and now “omicron” variants, the proclaimed protection by the novel vector-DiCoReTh-injections is becoming more and more doubtful as the probability of spreading the virus not only equalizes in recipients of the experimental DiCoReTh-injections, but seems likely to greatly surpass infections in unvaccinated persons (Chau et al., 2021). In the instance of the “delta” variant, the health care professionals studied in the hospital setting had

viral loads of breakthrough Delta variant infection . . . 251 times higher than those of cases infected with old strains detected between March–April 2020. Time from diagnosis to PCR negative was 8–33 days (median: 21). Neutralizing antibody levels after vaccination and at diagnosis of the cases were lower than those in the matched uninfected controls. There was no correlation between vaccine-induced neutralizing antibody levels and viral loads or the development of symptoms. . . . Breakthrough Delta variant infections are associated with high viral loads, prolonged PCR positivity, and low levels of vaccine-induced neutralizing antibodies, explaining the transmission between the vaccinated people (Chau et al., 2021).

In the case of vector DiCoReTh-injections, this occurs within three months of the last vaccination, whereas for mRNA DiCoReTh-injections, the waning effect is only slightly delayed (Mallapaty, 2021). It can't be excluded in the long run that this novel class of DiCoReTh-injections will fail altogether due to continuously mutating subspecies. From this perspective, mass vaccination does not make sense at all as a large part of the population is already sufficiently protected by natural infections (Reiss and Bhakdi, 2020).

5.0 Natural Immunity Is Better

As early as 2020, Gomes et al. reached the conclusion that people who have natural immunity are not susceptible to the virus and therefore do not become sick. Rather, by realistic modelling of available data, a maximum of 7–18% of the population will become infected with SARS-CoV-2, implying that herd immunity is achieved already at that level. Hence, indifferent mass vaccination must also be evaluated from this

⁶ VAERS data released by the Centers for Disease Control and Prevention (CDC) showed that between Dec. 14 2020 and Aug. 27 2021, for the US alone a total of 650,077 total adverse events were reported, including 13,911 deaths out of roughly 357 million doses administered (equivalent of 179 million fully vaccinated US-citizens receiving two doses), which translates to an adverse effect rate of 0.36%. EudraVigilance on adverse reactions due to mRNA and Vector Vaccines (May 22 2021) lists 12,184 fatalities and 1,196,190 injuries.

Moderna:
https://dap.ema.europa.eu/analytics/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Substance%20High%20Level%20Code%22&P3=1+40985312

Biontech:
https://dap.ema.europa.eu/analytics/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Substance%20High%20Level%20Code%22&P3=1+42325700

AstraZeneca:
https://dap.ema.europa.eu/analytics/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Substance%20High%20Level%20Code%22&P3=1+40995439%20

Janssen:
https://dap.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Substance%20High%20Level%20Code%22&P3=1+42287887

perspective, as it erodes herd immunity (particularly, as vaccinating young individuals adversely affects their innate immunity). This is especially relevant since lasting immunity to COVID-19 is suggested with infections without symptoms and even after mild illness; i.e., the normal rise in antibody levels is a consequence of infection. Antibody-producing cells are found even 11 months after the onset of initial symptoms, demonstrating that SARS-Cov-2 infections elicit a strong immune response in humans (Turner et al., 2021). As Coronaviruses have been around for decades, about one-quarter of people have antibodies from such precursor versions that can bind to the SARS-CoV-2, thereby neutralizing it quite efficiently, thus herd immunity has already been established years ago (Jones, 2020). On top of that, it has been shown that patients with IGA deficiency do not have a worse prognosis than healthy individuals (Naito et al., 2020). This, in turn, would indicate that lymphocytes are responsible for the immune reaction more so than the antibodies, which calls into question vaccination which should induce them.

5.1 Still Being Overlooked Though Known to Be Superior

Throughout the management of the current “pandemic”, natural immunity has been “more or less neglected. The USA, so far, does not recognise any immunity through natural infection, even though the CDC itself admits some effectiveness of natural immunity after infection. Cohort studies indicate an 80%–90% reduction in incidence for at least 6 months after infection among antibody-positive persons (CDC, 2021b). Still, the CDC recommends vaccination of this group also without further stipulations (CDC, 2021c). The question has to be raised why this is the case. Rooted in a firm push-back against the way Sweden and Great Britain were handling the “pandemic” in the beginning, and subsequently against any quest for so-called “herd immunity” without vaccines of some kind, the John Snow Memorandum proclaimed the danger of trusting natural immunity and dismissed any public health value in it (Alwan et al., 2020). Even the epidemiological term “herd immunity” itself started to be frowned upon and politically charged, which resulted in a general distrust of natural immunity. Fortunately, the EU policies recognize natural immunity to some degree. Proof of a COVID-19 infection through a positive PCR test, or in some countries with a more trustworthy serological antibody count, results in a “recovered” status for a set number of months and subsequently requires no shot — by policy in some EU-states — but at least one dose of some DiCoReTh-injection remains a general requirement for a person to be considered “fully vaccinated” (EC, 2021b). Nonetheless, it is noteworthy that the EU policies acknowledge natural immunity to some degree.

5.2 Infected Persons Not Helped by DiCoReTh-Injections

When immunity is acquired through infection, vaccination seems to bring little or no benefit, but it does bring with it risks associated with the side effects and possible long-term reactions the DiCoReTh-injection may cause (Bock, 2021). Menni et al (2021) found in their study, that systemic side effects after vaccination were more common in individuals with previous infections than among those without known infection. This again shows the problem with the undifferentiated, blanket approach of the current DiCoReTh-injection campaign. It does not reflect a thoughtful risk-benefit-analysis and exposes a large group of the population to a DiCoReTh-injection they likely do not need, and exposes them to a higher risk of adverse side effects while at the same time using up DiCoReTh-injection doses that could be beneficial to risk groups.

5.3 The Fatality Rate for COVID-19 Greatly Over-Estimated

Relating all these aforementioned aspects to the hypothesized claims that the “pandemic” will result in outstanding numbers of fatalities, it is further corroborated that SARS-CoV-2 is not the “deadly” virus as initially proclaimed, because, in the vast majority of cases, it did not even lead to severe illness and/or serious sequelae in healthy individuals. Moreover, SARS-CoV-2 under normal circumstances does not come

into contact with the bloodstream. In the case of an intramuscular injection, however, such a transmigration occurs rather frequently (Hassett et al., 2019). In that case, affected endothelial cells could be stimulated to synthesize the genetic material and present the spike protein via the MHC-I pathway on their cell surface. In capillaries, where blood flow velocity is rather low, this can easily result in Lymphocyte interaction (Chen et al., 2020), leading to tiny, localized blood clots, which ultimately result in micro-thrombosis even up to four weeks following vaccination (Hafeez et al., 2021). In the case of a previously acquired COVID-19 infection, CD8 lymphocytes are already present in the blood of the affected individual. Thus, the risk of cross-reactions after vaccination are real (Grifoni et al., 2020; Sekine et al., 2020; Nelde et al., 2020;). Since cases of thrombocytopenia have already been described (Zhang et al., 2020c; Lippi et al., 2020), this is a serious development that is cause for concern, especially in the case of RNA vaccination (Grady, 2021). Therefore, the need to receive a SARS-CoV-2 jab is uncalled for (Reiss and Bhakdi, 2020).

5.4 DiCoReTh-Injections for Children and Infants?

Given the emergency approval status granted to these novel DiCoReTh-injections, anyone exposed to one of them needs to be made aware that he or she is participating in a global field trial equivalent to a phase III-traditional vaccine safety study.⁷ Although as troubling as compulsory vaccination of medical personnel is — as it has been enforced by law in some EU-countries such as Italy (GU, 2021) — even more threatening is the currently planned expansion of the vaccination program to include children, infants, and pregnant women. The latter seems particularly strange because hardly any COVID-19 cases have been documented in children so that the risk of mortality in those groups is almost zero from any circulating virus (Ioannidis 2020). The idea to include this share of the population in the vaccination program is a clear indication that authorities don't understand this “pandemic” at all. Unfortunately, this will no longer be the case once children and the unborn babies of pregnant women who happen to be exposed to one or more shots of any DiCoReTh-injection. It is reasonable to suppose that in children the spike protein can i) bypass the innate immune system, ii) enter the bloodstream, and, given the encapsulating LNP layer, iii) be even more toxic in children than adults. In such a scenario, the risk-benefit ratio becomes unreasonable (Kostoff et al., 2021). A study published a year ago emphasizes the risk of contracting acute and chronic conditions during the first 12 months of post-partum life when all the recommended traditional vaccines are administered (Hooke and Miller, 2020). Since COVID-19 is not a childhood disease — as it primarily affects the elderly — vaccination in the age-group <40 is not at all justified. Given what is already known of the DiCoReTh-injections deployed in recent months, health specialists and parents should be cautious. On top of that and according to the hygiene hypothesis, young children should also refrain from wearing masks or being engaged in excessive hygiene, as such practices are associated with epigenetic hyperexpression of various genes, which inevitably leads to a weakening of the immune system that can persist for decades (Olszak et al. 2012).

5.5. Bossche Says Vaccination During a Genuine Pandemic Cannot Work

At a recent plenary lecture at an international vaccine conference, Vanden Bossche (2021) expressed concern about mass vaccination during a pandemic given the obvious fact that traditional vaccines, as well as the experimental DiCoReTh-injections, are all designed for prophylactic use. They do not have the power to kill a disease agent but rather contain all or part of one, or some product of a pathogen, that is supposed to stimulate antibody production against the actual cause of some targeted disease. As such, according to

⁷ Why was Israel able to provide this new vaccine to its population so quickly, starting as early as January 2021? The *Real-World Epidemiological Evidence Collaboration* signed by Pfizer and the Israeli Ministry of Health provides vaccines for its entire population, and in return the manufacturer receives an undisclosed payment along with the data on the vaccine's safety and efficacy, making Israel *de facto* the first large-scale field laboratory (Birnhack, 2021).

Vanden Bossche, vaccines of any type are not an efficient way to control an ongoing pandemic. They may be sensibly deployed to prevent one in the future, but not to halt one already in progress. He therefore advised that vaccination should never be used on a large scale where the population has already been exposed to widespread infection and the challenges to the natural immune functions already under stress.

His concerns are further supported by observations that the diversity of SARS-CoV-2 antibodies naturally produced is dampened in the population by mass vaccination (Niesen et al., 2021). That result was also observed by Chau et al. (2021) who found that “neutralizing antibody levels after vaccination” were lower in vaccinated health care workers who became infected with a “Delta” variant which they carried at levels 251 times higher than persons infected with a prior, and distinct variant. The implication is that vaccinated persons may not only have suppressed antibody production against a novel variant of the disease condition that the “vaccine” supposedly protects them from, but, given the impact of the DiCoReTh-injection itself — they got two doses of the Astra-Zeneca adenovirus, viral vector “vaccine” (the type depicted at the right hand side of our Figure 2 on page 180) — they may become a reservoir for and the source of a new variant of the targeted disease agent. Significantly, the health workers who had experienced the “breakthrough Delta variant infection” all became carriers of a variant that was “phylogenetically distinct from the contemporary Delta variant” that had previously proved to be more infectious than the “Alpha” variant of SARS-CoV-2.

5.6 Artificial Exposure to Viruses Speeds Mutant Production

Regardless of the proclaimed high efficacy by DiCoReTh-injection producers, Bossche’s expressed concern was rooted in the fact that vaccination on a large scale both accelerates and amplifies viral mutation rates. That is to say, new variants compared to the original strain have a better chance to increase their reservoir (see the Chau et al. study) thereby augmenting the viral replication capacity and spread of the new variants. All of this would turn the current global vaccination campaign into a program for advancing and amplifying the disease rather than reducing and dampening it. Although viruses cannot “think” and plan, the humans manipulating them and the DiCoReTh-injections impacting their downstream transformations and replications, with regard to the qS-c theory, really can account for a change in viral competencies within an organism to more rapidly produce and promote infective variants. Such programmed “mutants” are, according to the findings of Chau et al., better able to resist the antibodies produced by multiple exposures to a DiCoReTh-injection — a finding first reported by Farinholt et al. (2021). Moreover, recent data seem to even attest an opposite effect evidencing an increased risk of infection by the Beta, Gamma, or Delta variants after full vaccination, regardless of the “vaccine” used (Andeweg et al., 2021).

5.7 Explaining So-Called “Breakthrough” Infections

In addition, one should not forget that any vaccination is an “artificially induced infection” more suddenly impacting the whole organism. It is quite unlike the sigmoidal progression of a natural infection, and the “vaccine”, especially one of the DiCoReTh varieties, does not act at the normal sites of a natural infection (nose, throat, lungs). Contrary to natural infections, which yield short-lived antibodies to the common cold viruses, for instance, and life-time natural immunities in others (to measles, chicken-pox, and so forth), DiCoReTh-injected individuals may be building up replicants of some infectious agent indefinitely and with unknown long-term consequences. The results of Chau et al. as well as Farinholt et al. suggest that the antibodies generated to suppress whatever part of the SARS-CoV-2 virus the DiCoReTh-injection generates in great supply (assuming it works as intended, as it seemed to in health workers studied by Chau et al.) can stress natural immunity and consequently actually promote and speed up the generation of new variants of whatever infectious agent, or whatever part of one, the DiCoReTh-injections introduce into the body’s genetic systems during a period of weakened immunity. All this can potentially render the vaccinated individuals themselves more susceptible to infections by new variants — the so-called “breakthrough”

mutants — while at the same time the vaccinated individuals, as seen by Chau et al., become potential “super-spreaders” because they are producing a great deal of the new SARS-CoV-2 viral material. This threat scenario played out when DiCoReTh-injected health workers were found to have 251 times more viral load of the delta strain of SARS-CoV-2 than their unvaccinated counterparts.

6.0 The “Adjuvant Effect” of LNP Encapsulated DiCoReTh-Injections

It appears that the adjuvant-effect of DiCoReTh-injections is powerful. Whether it involves any named “adjuvant” in addition to the NLP carrying the mRNA into cells or the DNA induced production of some variant of the programmed disease component is unknown (Chung et al., 2020), or at least is, according to Chung et al. (see their “Conclusion” on p. 15532), undeclared by the makers of mRNA manufacturers. They do not name any specific adjuvants unless polysorbate and PEG are counted as such. However, as already noted, the mRNA and viral vector DNA products, presently being widely used in the world wide DiCoReTh-injection experiment, contain viral products encapsulated within the LNPs that can *themselves* act as adjuvants (Kim et al., 2021).

6.1 The Long and Perilous History of Adjuvants

The inclusion of well-known adjuvants consisting of aluminium-hydroxide or aluminium phosphate particles — which are easily detectable (Gatti and Montanari, 2015), and are known to cause adverse effects (Petrik et al., 2007; Tomljenovic & Shaw, 2011; Shaw et al., 2014; Butnaru & Shoenfeld, 2015; Gherardi et al., 2019; Crépeaux et al., 2020) — is particularly relevant for children up to the age of five who will typically have already been exposed to multiple doses of vaccines containing such adjuvants. All this, before potentially being exposed to DiCoReTh-injections that are known to have deleterious effects on the

6.2 Blaylock’s “Cytokine Storm” Playing Out




Figure 5a. Presence of aluminum compounds in the brain of deceased babies. Aluminum particle most likely aluminum-hydroxide.




Figure 5b. Debris of aluminum-phosphate compounds commonly used as adjuvants in vaccines.

Figures 5a and 5b contain two images along with elemental analysis taken with a field-emission source operated in environmental SEM mode equipped with electron-backscatter diffraction camera and X-ray energy drift spectrometer (EDS), which reveal the xenobiotic particles in brain tissue samples from prematurely deceased newborns. A similar investigation that likewise used environmental electron microscopy (ESEM) to study the composition of mRNA and vector “vaccines” revealed that these DiCoReTh-injections contain components that are not mentioned in the instruction leaflet (TSC, 2021). The identified substances are known for their bio-incompatibility by adversely affecting blood circulation, and vascular endothelium, contributing to the formation of thrombi, as well as increasing the risk of hemorrhaging. Nanoparticles such as graphene, regarded themselves as adjuvants (Xu et al., 2016; Cao, 2020; Chung et al., 2020) are known to induce pro-inflammatory cytokine expression — consider Blaylock’s (2021) “cytokine storm” (also see Fleming, 2021) — and in combination with PEG supposedly to improve elimination from the body (Palmieri et al., 2019). However, the DiCoReTh-injections are actually designed to disperse the LNPs and their payloads throughout the body (Kostoff et al., 2021). Graphene oxide used to induce a biomolecular corona can be toxic as it causes LDH leakage, results in decreased levels of glutathione and associated peroxides, suppresses mitochondrial membrane potential, slows ATP synthesis, and increases DNA damage (Gurunathan et al., 2019). Such nanomaterials are known to cross the blood brain barrier, enter the brain, and potentially induce strokes, and/or cerebral hemorrhages, while also damaging the endothelium of the heart muscle triggering a rise in myocarditis (Mevorach et al., 2021) and pericarditis cases among the young (Rose et al., 2021), predominantly affecting males (Mevorach et al., 2021). Indeed, both peri- and myocarditis are the most commonly observed adverse effects among mRNA-based DiCoReTh-injections amounting to 79.2% and 87.2% respectively (Hajjo et al., 2021).

7.0 Socio-Political Implications and Demographics

Several governments within the EU are still concentrating on and intensifying DiCoReTh-injection campaigns for people aged 65 years or older (EDCD, 2018). Italy is one of various COVID-19 epicenters and is not an exception to the continued focus of DiCoReTh-injections for the elderly population (Madl et al., 2021). Some 20.3% (225,316 of the 1,109,933 inhabitants) of the residents in the COVID-19 hotspot province of Bergamo were already 65 years or older at the onset of this “pandemic”. A complicating fact for that elderly population in Bergamo was that during the 2019–2020 period, 185,000 doses of influenza vaccine were ordered for this age group (BN, 2019a) — a bracket with a vaccination coverage rate of 52.7% (Mereckiene, 2018). In that same age group, about 118,742 individuals would have received a flu-jab and 34,000 of them (BN, 2019b) would have undergone meningitis vaccination (Madl et al., 2021). Given the potential for some significant percentage receiving either the flu or meningitis shots, or both of them, it was to be expected that they would also be more susceptible to COVID-19 infections. Later when the DiCoReTh-injections were added into the picture, even higher injury rates for those individuals would be expected (Cowling et al 2012; Wolff, 2020). All this was done in spite of the fact that during the 2019 flu

season according to Eurostat (2020), meningitis vaccinations were already known to be associated with complications when administered to individuals showing flu-like symptoms. This sort of interactive effect was not in fact new (Wood et al., 1995; Liu et al., 2017). So the question arises, did this older population in Bergamo, especially in the capital city of that province, experience such a high rate of COVID infections because of the high rate of exposure to artificially injected pathogens known to interact negatively?

7.1 Injection and Infection Rates

Only Spain, Belgium, Ireland, the Netherlands, and the UK score higher than Italy in the percentage of persons vaccinated and have likewise been hit hard during the COVID-19 waves as seen in a preprint article (EBMPHET, 2020) relating COVID-19 incidence to vaccination coverage rates (VCRs). According to that paper, the UK, the Netherlands, Belgium, Spain and Italy (among other countries) reveal a statistically significant ($p < 0.05$) positive correlation between VCR and the incidence of SARS-CoV-2 infections, as well as mortality in those aged 65 and up. Similar correlations between VCR and case fatality rate (CFR) have been noted for Europe in general. The editor of the *British Medical Journal* (Doshi, 2020a, 2020b) highlights problems associated with current DiCoReTh-injections as applied in elderly population that have not been properly addressed: for one, he points out that none of the “vaccine” trials has been designed to achieve a significant reduction in hospital admissions, intensive care unit treatments, or deaths. Also, he notes that in the absence of sufficient data analysis for persons in the over-65 age bracket, they should not be forced to receive the experimental DiCoReTh-injections. Accordingly, we are prompted to ask why are such experimental DiCoReTh-injections being pre-financed and produced with outrageously aggressive government funding while the privately owned companies that are developing and producing the DiCoReTh-injections are raking in profits in the billions of dollars and are protected from any kind of accountability to the general public — the people footing the bill?

7.2 Evident Design Flaws Ignored?

The current global use of the new technology DiCoReTh-injections, all of them operating in the US under emergency use authorization (EUA) and elsewhere under some equivalent emergency provision, was already beginning to reveal major design flaws in the form of dramatic side effects (Salah and Mehta, 2021) even when only a small percentage of the world’s population had been vaccinated (EMA, 2021b).⁸ Documented cases of hypothyroidism (Kaur et al., 2021) and premature deaths (EudraVigilance, 2021; VAERS, 2021 — see also Figure 1) have not been properly acknowledged or addressed by authorities. Although several countries in Europe as well as the USA halted and/or restricted use of DiCoReTh-injections to certain population groups after repeated cases of cerebral venous sinus thrombosis (CVST) were documented in combination with low levels of blood platelets (thrombocytopenia — see Schuchat, 2021; Nicolas, 2021; EMA, 2021a), the current push for world-wide mass vaccination has overwhelmed reasonable constraints. While any temporary moratorium on the problematic DiCoReTh-injections would certainly be recommended by persons looking thoughtfully at findings by independent researchers who do not have conflicts of interest causing them to prefer certain outcomes above others, all of the foregoing causes us to raise the question of whether such untested DiCoReTh-injections should be used in any kind of preventative care. When is it reasonable to experiment with human genetics using procedures known to produce conditions such as thrombocytopenia, myocarditis, pericarditis, not to mention a host of

⁸ Given the steady rise in confirmed myocarditis cases (Gargano et al. 2021) it is very likely that the current class of gene-based DiCoReTh-injections could lose their currently tentative EUA approval; experience from the past with cyclo-oxygenase-2 (COX-2) inhibitors associated with an increased risk of thrombotic events (Bresalier et al. 2005) have resulted in legal battles in which the producers of the drug was forced to release billions of dollars in compensation.

autoimmune diseases, and a greater number of deaths reported under the VAERS system than for all the previous vaccines in all the prior years on record combined (Figure 4a)?

Conclusions

Genetic DNA vector or mRNA injections, especially those termed DiCoReTh-injections in this paper, involve substantial risks that cannot be properly assessed without cumulative long-term data, and yet these so-called “vaccines” were associated with significant side effects even while they were still in their Warp Speed developmental phase before 2021. The mass use of these rapidly approved DiCoReTh-injections raises many questions — foremost among them is why adequate safety testing has not been undertaken and why there has been no open public discussion, much less the sort of debate that renown critics with a scientific background have persistently initiated (e.g. by Prof. Sucharit Bhakdi and colleagues via their NGO (MWGFD, 2021), Dr. Wolfgang Wodarg via his multilingual platform (Wodarg, 2021), or Nobel laureates such as Prof. Luc Montagnier and Prof Michael Levitt (Stecklow & Macaskill, 2021) as well as renown lawyers such as Robert F. Kennedy, Jr. (CHD, 2021), and Dr. Reiner Fuellmich (Fuellmich, 2021), just to name a few). The prevailing tunnel vision, disregarding all warning signs being pointed out consistently by independent researchers who have no vested interest in outcomes — other than wanting themselves and their children to be safe from medical harms — is a dangerous social phenomenon. Such single-minded pursuit of monetary profits and the usurpation of human rights and freedoms — have no place in scientific circles and especially in medical research.

While the processes of human protein biosynthesis are well understood, the introduction of the DiCoReTh-injections aimed at manipulating human genetic systems at the level of active mRNA and nuclear DNA may have already unleashed adverse potentials that are beyond anyone’s control. The precautionary principle should be paramount here, and as always, the potential to do harm must be weighed against any promised benefits. The thrombosis cases — along with a host of other disease conditions, life-threatening disorders, and many deaths that are directly attributable to DiCoReTh-injections have already occurred in Europe and the USA — illustrate the drama playing out in real time with the DiCoReTh-injections as the main protagonists while various governmental power-brokers, corporate media and marketing moguls, as well as medical experts pull the strings. Even the classical inactivated components in traditional vaccines are not without risks, especially from the problematic adjuvants, excipients, animal proteins, etc., that are known to pose short-term and long-term threats. However, the DiCoReTh-injections, because of their direct involvement in genetic re-writing turned loose inside human bodies, ups the ante exponentially as Mae-Wan Ho pointed out over the last couple of decades in many of her insightful publications (see Ho, 1998, 2013, 2014). Moreover, the use of a prophylactic strategy *after a real world-wide pandemic is well underway* would be like closing the barn door after all the horses are long gone.

DiCoReTh-injections are *de facto* unsuitable as tools to prevent what has already happened. It has been feared that mass vaccination is only speeding up SARS-CoV-2 diversification and, thus, ensuring its escape from all existing preventive measures. Must there be an unending series of booster shots trying to chase down the SARS-CoV-2 variants that are appearing much faster than the chasing shots and boosters can be produced? More importantly, how will the hopelessly outdistanced boosters ever catch up with the diversity of SARS-CoV-2 variants flying like bats from a bottomless pit? In view of all the risks, what compensating benefits can world-wide DiCoReTh-injections (or some other variety of genetic modifications) really offer? Where are the benefits? One shot was not enough. According to recent research done at the Francis Crick Institute a 5-6 fold reduction in neutralizing antibodies in patients with a two-dose mRNA DeCoReTh injection was observed (see supplement section of Wall et al, 2021). Given this finding and the millions of DeCoReTh cases pursued so far in the UK alone, one could regard Cole’s prediction with thousands of emerging endometrial cancer cases as not so far-fetched at all (Wilson, 2021). In other words, two

DeCoReTh injections are not so effective as proclaimed, but more harmful than one (see Figure 6), so how can a series of three shots, four, or an unending series of “boosters” set things right? Also, what ever happened to the known fact that our natural immune defenses can defeat more than 99% of the infectious diseases to which we are exposed? Why not concentrate on enhancing natural immunity?




Figure 6. Data reported in this figure are from the heavily vaccinated population of Alberta Canada. The time from first dose (left column) to second dose (right column) of DeCoReTh injections until a COVID-19 diagnosis by age group on the time line. Note: the first dose data include people diagnosed as COVID-19 cases prior to the date of their second dose; a) top: all cases showing the immediate impact of the 1st injection whereas the delayed impact after the 2nd injection only became manifest after several months; b) center: those who were hospitalized — here too the time delay is observed after the 2nd injection; c) bottom: a similar delayed impact exists for reported deaths from COVID-19 (modified after GoA, 2022).

Many age groups are at minuscule risk from COVID-19, and even with high SARS-CoV-2 infection rates and the multiple variants of the virus that have already been identified, COVID-19 does not appear to have been significantly more of a risk factor than ordinary flu viruses. Even with all the engineering that went into promoting this world wide “pandemic” (see Fleming, 2021; also, Kennedy, 2021), our natural immune defenses seem capable of handling everything it has thrown at us. Hundreds of millions have even survived, so far, and seem to have overcome the extra-special risks from DiCoReTh-injections that were schooled by the decades of research that went into the creation of SARS-CoV-2 and the spike producing “vaccines” (Fleming, 2021; Kennedy, 2021). Does the global push for mass vaccination make sense in the fight against the COVID-19 pestilence in light of the known risks of DiCoReTh-injections? Is the relative low risk to individuals a sufficient basis for shutting down whole countries, and trying to shut down the entire world? There is also an urgent need for honest and unbiased data collection and analysis of naturally occurring immunity in the population. Artificial immunization is certainly a valuable tool if done properly, but it requires a solid scientific basis, and in no way can justify running rough shod over human rights about what goes into our own bodies. The current vaccination push, as well as the “zero-COVID” strategy is so far from being any kind of scientific necessity that it can only qualify as a political preference based on the marketing of pharmaceuticals (Kulldorff et al., 2020; Broudy, 2021; Broudy and Arakaki, 2020; Broudy and Hoop, 2021).

The need for a more informed approach to the “pandemic” is evident. Consideration of natural immunity in crafting public health policies is essential and cannot reasonably be seconded to DiCoReTh-injections on account of the obscene profits they offer to the backgrounded power-brokers. Natural immune powers built into human beings by our Creator along with certain “unalienable rights” (according to the American Declaration of Independence) are as real as our bodies are, and are valid wedges with which to chock the wheels of the fearful promoters of this “pandemic” — witness [Event201 \(2019\)](#) with its named participants as documented and recorded — before their arguments can possibly take flight again. We need research, reasoned analysis, and level-headed debates to put the fear of COVID-19 into clear perspective and to put the quietus to the absurdly false claim that DiCoReTh-injection is an absolute must. Doing this will ease financial pressure on developing countries that are currently being driven toward an unnecessary and incredibly costly DiCoReTh-injection campaign. An open, evidence-based discussion of COVID-policies is most urgently needed to stop the drift towards politically influenced and market-driven management of issues,⁹ that are scientific in nature.

Conflicts of Interest

The authors have no conflict of interest to declare.

References

- Adiguzel, Y., (2021). Molecular mimicry between SARS-CoV-2 and human proteins. *Autoimmunity Reviews*, 20(4), 102791. <https://doi.org/10.1016/j.autrev.2021.102791>
- Agmon-Levin, N., Paz, Z., Israeli, E., & Shoenfeld Y. (2009) Vaccines and autoimmunity. *Nat Rev Rheumatol*, 5(11):648-52. <https://doi.org/10.1038/nrrheum.2009.196>.

⁹ The continuing global pandemic is important for investor confidence. There is concern about future demand as the latest wave of infections declines. Investors worry that the pandemic could be over in 2022, and what then? (Blankenhorn, 2021).

- Alwan, N.A., Burgess, R.A., Ashworth, S., Beale, R., Bhadelia, N., Bogaert, D., Dowd, J., Eckerle, I., Goldman, L.R., Greenhalgh, T., Gurdasani, D., Hamdy, A., Hanage, W.P., Hodcroft, E.B., Hyde, Z., Kellam, P., Kelly-Irving, M., Krammer, F., Lipsitch, M., McNally, A., McKee, M., Nouri, A., Pimenta, D., Priesemann, V., Rutter, H., Silver, J., Sridhar, D., Swanton, C., Walensky, R.P., Yamey, G., & Ziauddeen, H. (2020). Scientific consensus on the COVID-19 pandemic: we need to act now. *Lancet* 396(10260): e71-e72. [https://doi.org/10.1016/S0140-6736\(20\)32153-X](https://doi.org/10.1016/S0140-6736(20)32153-X). The corresponding “John Snow Memorandum” is available online <https://www.johnsnowmemo.com/john-snow-memo.html> (accessed: Feb. 2021)
- Andeweg, S.P., Vennema, H., Veldhuijzen, I.K., Smorenburg, N., Schmitz, D., Zwagemaker, F., SeqNeth, Molecular surveillance group, RIVM COVID-19 Molecular epidemiology group, van Gageldonk-Lafeber, A.B., Chantal, S.H., Reusken REM, Knol, M.J., & Eggink, D. (2021). Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals. *medRxiv*: 244530109. <https://doi.org/10.1101/2021.11.24.21266735>
- Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A., Simons, D., Blomquist, P.B., Dabrera, G., Myers, R., Ladhani, S.N., Amirthalingam, G., Gharbia, S., Barrett, J.C., Elson, R., Ferguson, N., Zambon, M., Campbell, C.N.J., Brown, K., Hopkins, S., Chand, M., Ramsay, M., & Lopez Bernal, J. (2021). Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. *medRxiv*, 2021.12.14.21267615. <https://doi.org/10.1101/2021.12.14.21267615>;
- Aubrit, F., Perugi, F., Léon, A., Guéhenneux, F., Champion-Arnaud, P., Lahmar, M., & Schwamborn K (2015). Cell substrates for the production of viral vaccines. *Vaccine*, 33(44): 5905-5912. <https://doi.org/10.1016/j.vaccine.2015.06.110>
- Arvay, C. (2020). Genetische Impfstoffe gegen COVID-19: Hoffnung oder Risiko? [Genetic Vaccines Against COVID-19: Hope Or Risk?] *Schweizer Ärztezeitung*, 101(2728): 862-864. <https://doi.org/10.4414/saez.2020.18982>
- Avci, E., & Abasiyanik, F. (2021). Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up? *J Autoimmun* 125: 102745. <https://doi.org/10.1016/j.jaut.2021.102745>
- Bahl, K., Senn, J.J., Yuzhakov, O., Bulychev, A., Brito, L.A., Hassett, K.J., Laska, M.E., Smith, M., Almarsson, Ö., Thompson, J., Ribeiro, A.M., Watson, M., Zaks, T., & Ciaramella, G. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. *Mol Ther*, 25(6):1316-1327. <https://doi.org/10.1016/j.ymthe.2017.03.035>
- Baum, C., Kustikova, O., Modlich, U., Li, Z.X., & Fehse, B. (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. *Hum Gene Ther*, 17(3): 253-263. <https://doi.org/10.1089/hum.2006.17.253>
- Birnhack, M. (2021). Who Controls COVID-Related Medical Data? Copyright and Personal Data. *IIC* 52: 821–824. Doi: 10.1007/s40319-021-01067-5; related source file: <https://govextra.gov.il/media/30806/11221-moh-pfizer-collaboration-agreement-redacted.pdf> (accessed: Feb. 2021)
- BL, (2020). *Dr. Kary Mullis—Inventor of PCR*. Benevolent Lite. <https://www.youtube.com/watch?v=7j8STZQWF4> (accessed: Dec. 2021)
- Blankenhorn, D. (2021). Novavax Stock Needs a Longer Pandemic as Investor Patience Wears Thin. Investor Place (accessed: Sept. 2021): <https://markets.businessinsider.com/news/stocks/novavax-stock-needs-a-longer-pandemic-as-investor-patience-wears-thin-1030833455>
- Blaylock, R.L. (2021). Excitotoxicity (immunoexcitotoxicity) as a critical component of the cytokine storm reaction in pulmonary viral infections, including SARS-CoV-2. *International Journal of Vaccine Theory, Practice, and Research*, 1(2), 223–242. <https://ijvtp.com/index.php/IJVTPr/article/view/14>
- Bock, J. (2021). Vaccinating people who have had COVID-19: why doesn’t natural immunity count in the US? *BMJ*, 374: n2101. doi: 10.1136/bmj.n2101
- BN, (2019a). Vaccino antiinfluenzale: a Bergamo ordinate 185 000 dosi. Bergamo News. https://www.bergamonews.it/2019/10/21/vaccinazione-antinfluenzale-a-bergamo-ordinate-185-000-dosi-di-vaccino/332164/?fbclid=IwAR1glyhj6RQOqOp8YbBf5oLMrkn18P4DyQ-k_GsVicLA-vWuTFwiITSUnzM (accessed: May 2020)
- BN, (2019b). Emergenza Meningite, Vaccinate 34mila persone tra Brescia e Bergamo. Bergamo News. https://www.bsnews.it/2020/01/18/meningite-vaccinate-34mila-persone-tra-brescia-e-bergamo/?fbclid=IwAR1bsaQy4Ppd21k4WLPkYYMnpiBY5tEtdk5gEH25rZfrGjTDyL_RnxNytNU (accessed: May 2020)

- Bresalier, R.S., Sandler, R.S., Quan, H., Bolognese, J.A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M.A., & Baron, J.A. (2005). Adenomatous polyp prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med*, 352(11): 1092-1102. <https://doi.org/10.1056/NEJMoa050493>
- Broudy, D. (2021). Vaccine development and social control: A psychopathology of impaired reasoning in the global push for mass compliance. *International Journal of Vaccine Theory, Practice, and Research*, 2(1), 93–124. <https://ijvtpr.com/index.php/IJVTPr/article/view/23>
- Broudy, D., & Arakaki, M. (2020). Who wants to be a slave? The technocratic convergence of humans and data. *Frontiers in Communication*, 5. <https://doi.org/10.3389/fcomm.2020.00037>
- Broudy, D., & Hoop, D. (2021). Messianic mad men, medicine, and the media war on empirical reality: Discourse analysis of mainstream COVID-19 propaganda. *International Journal of Vaccine Theory, Practice, and Research*, 2(1), 1–24. <https://ijvtpr.com/index.php/IJVTPr/article/view/22>
- Broudy, D., & Kyrie, V. (2021). Syllogistic reasoning demystifies evidence of COVID-19 vaccine constituents. *International Journal of Vaccine Theory, Practice, and Research*, 2(1), 149–172. <https://ijvtpr.com/index.php/IJVTPr/article/view/23>
- Bruno, R., McCullough, P.A.I., Villa, T.F., Henrion-Caude A, García-Gasca, T., Zaitzeva, G.P., Priester, S., Albarracín, M.J.M., Sousa-Escandon, A., Mirones, F.L., Payeras-Cifre, B., Zaragoza-Velilla, A., Borini, L.M., Mas, M., Salazar, R., Schinder, E., Yahbes, E.A., Witt, M., Salmeron, M., Fernández, P., Marchesini, M.M., Kajihara, A.J., De La Riva, M.V., Chimenó, P.J., Grellet, P.A., Lisdero, M., Mas, P., Baudo, A.J.G., Retamoza, E., Botta, O., Brandolino, C.C., Sciuto, J., Avivar, M.C., Castillo, M., Villarroel, P., Poblete-Rojas, E.P., Aguayo, B., Macías-Flores, D.I., Rossell, J.V., Sarmiento, J.C., Andrade-Sotomayor, V., Stokes-Baltazar, W.R., Cedeño-Escobar, V., Arrúa, U., Farina del Río, A., Campos-Esquivel, T., Callisperis, P., Barrientos, M.E., Fiala, C., & Acevedo-Whitehouse, K. (2021). SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers. *Authorea*, preprint. <https://doi.org/10.22541/au.162136772.22862058/v1>
- Buchbinder, S.P., McElrath, M.J., Dieffenbach, C., & Corey, L. (2020). Use of adenovirus type-5 vectored vaccines: a cautionary tale. *Lancet*, 396(10260):e68-e69. [https://doi.org/10.1016/S0140-6736\(20\)32156-5](https://doi.org/10.1016/S0140-6736(20)32156-5)
- Buda, S., Preuss, U., Wedde, M., & Duerrwald, R. (2019). Effectiveness of vaccination against seasonal influenza — vaccine effectiveness (Wirksamkeit der Impfung gegen saisonale Influenza – Impfeffektivität), In: Report on the Epidemiology of Influenza in Germany, Season 2018/19 (Bericht zur Epidemiologie der Influenza in Deutschland, Saison 2018/19), Robert Koch-Institut, Berlin (FRG). <https://doi.org/10.25646/6232> <https://influenza.rki.de/Saisonberichte/2018.pdf> (accessed: July 2020)
- Burrell, S.A.M., & Exley, C. (2010). There is (still) too much aluminium in infant formulas. *BMC Pediatrics*, 10, 63. <https://doi.org/10.1186/1471-2431-10-63>
- Burrell, C.J., Howard, C.R., & Murphy, F.A. (2016) Fenner and White's Medical Virology, 5th ed. Academic Press Elsevier Publisher, San Diego (CA). ISBN 978-0-12-375156-0
- Butnaru, D., & Shoenfeld, Y. (2015). Adjuvants and lymphoma risk as part of the ASIA spectrum. *Immunologic Research*, 61(1–2), 79–89. <https://doi.org/10.1007/s12026-014-8622-0>
- Cabanillas, B., Akdis, C., & Novak, N. (2020). Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? *Allergy* 14711. <https://doi.org/10.1111/all.14711>
- Cao, W., He, L., Cao, W., Huang, X., Jia, K., & Dai, J. (2020). Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. *Acta Biomater*, 112:14-28. <https://doi.org/10.1016/j.actbio.2020.06.009>.
- Cappello, F., Gammazza, A.M., Dieli, F., de Macario E.C., Macario, A.J. (2020). Does SARS-CoV-2 Trigger Stress-Induced Autoimmunity by Molecular Mimicry? A Hypothesis. *J Clin Med*, 9(7): 2038. <https://doi.org/10.3390/jcm9072038>
- CDC, (2020). Weekly Updates by Select Demographic and Geographic Characteristics – Provisional Death Counts for Coronavirus Disease 2019 (COVID-19). Center for Disease Control. Centers for Disease and Control Prevention. https://www.cdc.gov/nchs/nvss/vsrr/COVID_weekly/index.htm (accessed: June 2020).

- CDC, (2021a). Emerging SARS-CoV-2 Variants” Centers for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html> (accessed: Jan. 2020)
- CDC, (2021b). Development of Antibodies and Immunity. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html> (accessed: Sept. 2021)
- CDC, (2021c). Interim Guidelines for COVID-19 Antibody Testing. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html> (accessed: Sept. 2021)
- Chang, M.C., Hur, J., & Park, D. (2020). Interpreting the COVID-19 Test Results: A Guide for Psychiatrists. *Am J Phys Med Rehabil*, 99(7): 583-585. <https://doi.org/10.1097/PHM.0000000000001471>
- Chau, N.V.V., Ngoc, N.M., Nguyet, L.A., Quang, V.M., Ny, N.T.H., Khoa, D.B., Phong, N.T., Toan, L.M., Hong, N.T.T., Tuyen, N.T.K., Phat, V.V., Nhu, L.N.T., Truc, N.H.T., That, B.T.T., Thao, H.P., Thao, T.N.P., Vuong, V.T., Tam, T.T.T., Tai, N.T., Bao, H.T., Nhung, H.T.K., Minh, N.T.N., Tien, N.T.M., Huy, N.C., Choisy, M., Man, D.N.H., Ty, D.T.B., Anh, N.T., Uyen, L.T.T., Tu, T.N.H., Yen, L.M., Dung, N.T., Hung, L.M., Truong, N.T., Thanh, T.T., Thwaites, G., & Tan, L.V. (2021). An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. *E-Clinical Medicine*, 41: 101143. <https://doi.org/10.1016/j.eclim.2021.101143>
- CHD (2021). Ending childhood health epidemics. Children's Health Defense. <https://childrenshealthdefense.org/> (accessed: Dec. 2021)
- Chen YY, Syed AM, MacMillan P, Rocheleau JV, Chan WCW (2020) Flow rate affects nanoparticle uptake into endothelial cells. *Adv Mater*, 32(24): e1906274. <https://doi.org/10.1002/adma.201906274>
- Chen, Y., Xu, Z., Wang, P., Li, X.M., Shuai, Z.W., Ye, D.Q., & Pan, H.F. (2021) New-onset autoimmune phenomena post-COVID-19 vaccination. *Immunology*, [ahead of print]. <https://doi.org/10.1111/imm.13443>
- Chung, Y.H., Beiss, V., Fiering, S.N., & Steinmetz, N.F. (2020). COVID-19 vaccine frontrunners and their nanotechnology design. *ACS Nano*, 14(10), 12522–12537. <https://doi.org/10.1021/acsnano.0c07197> Full text PDF 2021 available at <https://pubs.acs.org/doi/pdf/10.1021/acsnano.0c07197>
- Cerpa-Cruz, S., Paredes-Casillas, P., Landeros-Navarro, E., Bernard-Medina, A.G., Martínez-Bonilla, G., & Gutiérrez-Ureña, S. (2013). Adverse events following immunization with vaccines containing adjuvants. *Immunol Res*, 56(2-3): 299-303. <https://doi.org/10.1007/s12026-013-8400-4>
- Chiu, W.J., Chen, Y.C., Huang, C.C., Yang, L., Yu, J., Huang, S.W., & Lin, C.H. (2021). Iron hydroxide/oxide-reduced graphene oxide nanocomposite for dual-modality photodynamic and photothermal therapy in vitro and in vivo. *Nanomaterials*, 11(8), 1947. <https://doi.org/10.3390/nano11081947>
- CI, (2020). Province of Bergamo and city of Bergamo. Census Data from 2016. Comuni Italiani. <http://www.comuni-italiani.it/016/index.html> (accessed: May 2020)
- Coors, E.A., Seybold, H., Merk, H.F., & Mahler, V. (2005). Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. *Ann Allergy Asthma Immunol*, 95(6): 593-599. doi: 10.1016/S1081-1206(10)61024-1
- Cowling, B.J., Fang, V.J., Nishiur, H., Chan, K.H., Ng, S., Ip, D.K.M., Chiu, S.S., Leung, G.M., & Peiris, J.S.M. (2012). Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. *CID*, 54: 1778-1783. <https://doi.org/10.1093/cid/cis307>
- Crépeaux, G., Authier, F.J., Exley, C., Luján, L., & Gherardi, R.K. (2020). The role of aluminum adjuvants in vaccines raises issues that deserve independent, rigorous and honest science. *J Trace Elem Med Biol*, 62:126632. <https://doi.org/10.1016/j.jtemb.2020.126632>
- Desfarges, S., & Ciuffi, A. (2012). Viral integration and consequences on host gene expression. In: Witzany, G. (ed) *Viruses: Essential Agents of Life*, 147–175. Springer, Dodrecht (NL). https://doi.org/10.1007/978-94-007-4899-6_7
- De Melo, G.D., Lazarini, F., Larrous, F., Feige, L., Kornobis, E., Levallois, S., Marchio, A., Kergoat, L., Hardy, D., Cokelaer, T., Pineau, P., Lecuit, M., Lledo, P.M., Changeux, J.P., & Bourhy, H. (2021). Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. *EMBO Mol Med*, 13(8):e14122. <https://doi.org/10.15252/emmm.202114122>

- deVrieze, J. (2021). Pfizer's vaccine raises allergy concerns. *Science* 371(6524): 10-11.
<https://doi.org/10.1126/science.371.6524.10>
- Doerfler, W. (2021). Adenoviral vector DNA- and SARS-CoV-2 mRNA-based COVID-19 vaccines: Possible integration into the human genome — are adenoviral genes expressed in vector-based vaccines? *Virus Res*, 302: 198466.
<https://doi.org/10.1016/j.virusres.2021.198466>
- Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., & Shoenfeld, Y. (2021). The SARS-CoV-2 as an instrumental trigger of autoimmunity. *Autoimmun Rev*, 20(4):102792. <https://doi.org/10.1016/j.autrev.2021.102792>
- Doshi, P. (2020a). COVID-19 vaccine trial protocols released. *BMJ*, 371: m4058. <https://doi.org/10.1136/bmj.m4058>
- Doshi, P. (2020b). Will COVID-19 vaccines save lives? Current trials aren't designed to tell us. *BMJ*, 371: m4037.
<https://doi.org/10.1136/bmj.m4037>
- Eaton, A., Lewis, N., Fireman, B., Hansen, J., Baxter, R., Gee, J., & Klein, N. P. (2018). Birth outcomes following immunization of pregnant women with pandemic H1N1 influenza vaccine 2009–2010. *Vaccine*, 36(19), 2733–2739.
<https://doi.org/10.1016/j.vaccine.2017.08.080>
- EBMPHET Consortium, (2020.) COVID-19 Severity in Europe and the USA: Could the Seasonal Influenza Vaccination Play a Role? doi: 10.2139/ssrn.3621446. <https://ssrn.com/abstract=3621446> (accessed: June 2020)
- EC, (2021a). Commission identifies five promising candidate therapeutics. European Commission Press Release 29th June 2021;
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299 (accessed: June 2021)
- EC, (2021b). Questions and Answers – EU Digital COVID certificate.
https://ec.europa.eu/commission/presscorner/detail/en/QANDA_21_2781 (accessed: Sept. 2021)
- ECDC, (2021). Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA — first update. European Centre for Disease Prevention and Control; <https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf> (accessed: Feb. 2021)
- EMA, (2021a). AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. European Medical Agency. <https://www.ema.europa.eu/en/news/astrazenecas-COVID-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood> (accessed: Feb. 2021)
- EMA, (2021b). Online access to suspected side-effect reports. European Medical Agency.
http://www.adrreports.eu/de/search_subst.html → search for Covid-19 (accessed: Feb. 2020)
- EMA, (2021c). Assessment report: COVID-19 mRNA Biontec. Procedure No. EMEA/H/C/005735/0000.
<https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty> (accessed: Feb. 2021)
- EMA, (2021d). Assessment report: COVID-19 Vaccine Moderna. Procedure No. EMEA/H/C/005791/0000.
<https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax> (accessed: Feb. 2021)
- EMA, (2021e). Assessment report: COVID-19 Vaccine AstraZeneca. Procedure No. EMEA/H/C/005675/0000.
<https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-COVID-19-vaccine-astrazeneca> (accessed: June 2021)
- EMA, (2021f). Assessment report: COVID-19 Vaccine Janssen. Procedure No. EMEA/H/C/005737/0000
<https://www.ema.europa.eu/en/medicines/human/EPAR/COVID-19-vaccine-janssen> (accessed: March 2021)
- EudraVigilance, (2021). European database of suspected adverse drug reaction reports.
<https://www.adrreports.eu/en/search.html> (accessed June 2021)
- EuroMomo, (2022). European monitoring of excess mortality for public health action. <https://euromomo.eu/graphs-and-maps/> (accessed: Jan. 2022)
- EuroStat, (2020). Vaccination against influenza of population aged 65 and over. European Commission.
https://ec.europa.eu/eurostat/web/products-datasets/-/hlth_ps_immu (accessed: May 2020)

- Event201, (2019). A pandemic exercise to illustrate preparedness efforts. Media event hosted by Johns Hopkins Bloomberg School of Public Health, World Economic Forum, & Bill and Melinda Gates Foundation. (2019, October 18). <https://centerforhealthsecurity.org/event201/> (accessed Dec. 2021)
- Exley, C. (2017). Aluminum should now be considered a primary etiological factor in Alzheimer's disease. *Journal of Alzheimer's Disease Reports*, 1(1), 23–25. <https://doi.org/10.3233/ADR-170010>
- Farinholt, T., Doddapaneni, H., Qin, X., Menon, V., Meng, Q., Metcalf, G., Chao, H., Gingras, M.C., Avadhanula, V., Farinholt, P., Agrawal, C., Muzny, D.M., Piedra, P.A., Gibbs, R.A., & Petrosino, J. (2021) Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. *BMC Med*, 19(1): 255. <https://doi.org/10.1186/s12916-021-02103-4>
- Fleming, D.R.M. (2021). *Is COVID-19 a Bioweapon?: A Scientific and Forensic investigation*. Skyhorse Publishing (NY). ISBN 978-1-5107-7019-5
- Fuellmich R (2021) Internationale Rechtsanwaltskanzlei fuer Verbraucherschutz und Medizinrecht (Int. Law office for consumer protection and medical law). <https://www.fuellmich.com/> (accessed: Dec. 2021)
- Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012). Development and evaluation of AS03, an Adjuvant System containing α -tocopherol and squalene in an oil-in-water emulsion. *Expert Review of Vaccines*, 11(3), 349–366. <https://doi.org/10.1586/erv.11.192>
- Gardner, L., Dong, E., CSSE (2021). *The COVID-19 Testing Insight Initiative*. Coronavirus Resource Center. Center for Systems Science and Engineering at John Hopkins University. (accessed 20 Aug. 2021)
- Gargano, J.W., Wallace, M., Hadler, S.C., Langley, G., Su, J.R., Oster, M.E., Broder, K.R., Gee, J., Weintraub, E., Shimabukuro, T., Scobie, H.M., Moulia, D., Markowitz, L.E., Wharton, M., McNally, V.V., Romero, J.R., Talbot, H.K., Lee, G.M., Daley, M.F., & Oliver, S.E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, *MMWR Morb Mortal Wkly Rep*, 70(27): 977-982. <https://doi.org/10.15585/mmwr.mm7027e2>
- Gatti, A., & Montanari, S. (2015). *Case studies in Nanotoxicology and Particle toxicology*. Akademic Press Elsevier Publisher, London (UK); ISBN 9-780-128-01215-4
- Gherardi, R.K., Coquet, M., Cherin, P., Belec, L., Moretto, P., Dreyfus, P.A., Pellissier, J.F., Chariot, P., & Authier, F.J. (2001). Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. *Brain*, 124(Pt 9): 1821-1831. <https://doi.org/10.1093/brain/124.9.1821>
- Gherardi, R. K., Crépeaux, G., & Authier, F.-J. (2019). Myalgia and chronic fatigue syndrome following immunization: Macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. *Autoimmunity Reviews*, 18(7), 691–705. <https://doi.org/10.1016/j.autrev.2019.05.006>
- GISRS (2021) Influenza Laboratory Surveillance Information provided by the Global Influenza Surveillance and Response System, WHO. <https://apps.who.int/flumart/Default?ReportNo=10> (accessed Dec. 2021)
- GoA, (2021). COVID-19 Alberta statistics. Interactive aggregate data on COVID-19 cases in Alberta. Government of Alberta (CDN). <https://www.alberta.ca/stats/covid-19-alberta-statistics.htm#vaccine-outcomes> (accessed Jan. 2022). As of 14th of Jan. 2022 the interactive chart section is no longer available on the GoA-website, repository data access is only possible via the web-archive; <https://web.archive.org/web/20220114005412/https://www.alberta.ca/stats/covid-19-alberta-statistics.htm#vaccine-outcomes> (accessed Jan. 2022)
- Goldman, S., Bron, D., Tousseyn, T., Vierasu, I., Dewispelaere, L., Heimann, P., Cogan, E., & Goldman, M. (2021). Rapid progression of angioimmunoblastic T Cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report. *Frontiers in Medicine*, 8:798095. <https://doi.org/10.3389/fmed.2021.798095>
- Gomes, M.G.M., Corder, R.M., King, J.G., Langwig, K.E., Souto-Maior, C., Carneiro, J., Goncalves, G., Penha-Goncalves, C., Ferreira, M.U., & Aguas, R. (2020). Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. *medRxiv*, 2020.04.27.20081893. <https://doi.org/10.1101/2020.04.27.20081893>
- Grady, D. (2021). A Few Covid Vaccine Recipients Developed a Rare Blood Disorder, The New York Times. <https://www.nytimes.com/2021/02/08/health/immune-thrombocytopenia-COVID-vaccine-blood.html> (accessed: Feb. 2021)

- Grenfell, B.T., Pybus, O.G., Gog, J.R., Wood, J.L., Daly, J.M., Mumford, J.A., & Holmes, E.C. (2004). Unifying the epidemiological and evolutionary dynamics of pathogens. *Science*, 303(5656): 327-332. <https://doi.org/10.1126/science.1090727>
- Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., Marrama, D., de Silva, A.M., Frazier, A., Carlin, A.F., Greenbaum, J.A., Peters, B., Krammer, F., Smith, D.M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell*, 181(7):1489-1501.e15. <https://doi.org/10.1016/j.cell.2020.05.015>
- GU, (2021). Misure urgenti per il contenimento dell'epidemia da COVID-19, in materia di vaccinazioni anti SARS-CoV-2, di giustizia e di concorsi pubblici. (21G00056). Urgent measures for the containment of the epidemic of COVID-19, in the field of vaccinations against SARS-CoV-2, justice and public sector. *Gazzetta Ufficiale Serie Generale n.79 del 01-04-2021* <https://www.gazzettaufficiale.it/eli/id/2021/04/01/21G00056/sg> (accessed: May 2021)
- Gurunathan, S., Arsalan-Iqbal, M., Qasim, M., Park, C.H., Yoo, H., Hwang, J.H., Uhm, S.J., Song, H., Park, C., Do, J.T., Choi, Y., Kim, J.H., & Hong, K. (2019). Evaluation of graphene oxide induced cellular toxicity and transcriptome analysis in human embryonic kidney cells. *Nanomaterials* (Basel). 9(7): 969. <https://doi.org/10.3390/nano9070969>
- Guzik, T.J., Mohiddin, S.A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F.M., Madhur, M.S., Tomaszewski, M., Maffia, P., D'Acquisto, F., Nicklin, S.A., Marian, A.J., Nosalski, R., Murray, E.C., Guzik, B., Berry, C., Touyz, R.M., Kreutz, R., Wang, D.W., Bhella, D., Sagliocco, O., Crea, F., Thomson, E.C., & McInnes, I.B. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res*, 116(10): 1666-1687. <https://doi.org/10.1093/cvr/cvaa106>
- Haberecker, M., Schwarz, E.I., Steiger, P., Frontzek, K., Scholkmann, F., Zeng, X., Höller, S., Moch, H., & Varga, Z. (2021). Autopsy-based pulmonary and vascular pathology: pulmonary endotheliitis and multi-organ involvement in COVID-19 associated deaths. *Respiration*, 1-11. <https://doi.org/10.1159/000518914>
- Hajjo, R., Sabbah, D.A., Bardaweel, S.K., & Tropsha, A. (2021). Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients. *Vaccines* (Basel), 9(10):1186. <https://doi.org/10.3390/vaccines9101186>.
- Hassett, K.J., Benenato, K.E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B.M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M.J., Senn, J.J., Stanton, M.G., Almarsson, Ö., Ciaramella, G., & Brito, L.A. (2019). Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. *Mol Ther Nucleic Acids*, 15:1-11. <https://doi.org/10.1016/j.omtn.2019.01.013>
- Hasson, S., Al-Busaidi, J., & Sallam, T. (2015). The past, current, and future trends in DNA vaccine immunisations. *Asian Pac J Trop Biomed*, 5(5): 344-353. [https://doi.org/10.1016/S2221-1691\(15\)30366-X](https://doi.org/10.1016/S2221-1691(15)30366-X)
- Hirose, S., Hara, M., Koda, K., Natori, N., Yokota, Y., Ninomiya, S., & Nakajima, H. (2021). Acute autoimmune transverse myelitis following COVID-19 vaccination: A case report. *Medicine* (Baltimore). 100(51): e28423. <https://doi.org/10.1097/MD.00000000000028423>
- Ho, M.-W. (1999). *Genetic Engineering, Dream or Nightmare? The Brave New World of Bad Science and Big Business*, 2nd ed. Gateway Books, Dublin (IRL). ISBN 0-8264-1257-2
- Ho, M.-W. (2013). The new genetics and natural versus artificial genetic modification. *Entropy*, 15(11), 4748–4781. <https://doi.org/10.3390/e15114748>
- Ho, M.-W. (2014). Illuminating water and life. *Entropy*, 16(9), 4874–4891. <https://doi.org/10.3390/e16094874>
- Hsee, C.K., & Ruan, B. (2016). The Pandora Effect: The power and peril of curiosity. *Psychological Science*, 1:8. <https://doi.org/10.1177/0956797616631733>
- Hooker, B.S., & Miller, N.Z. (2020). Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders. *SAGE Open Med*, 8: 2050312120925344. <https://doi.org/10.1177/2050312120925344>
- Hafeez, M.U., Ikram, M., Shafiq, Z., Sarfraz, A., Sarfraz, Z., Jaiswal, V., Sarfraz, M., Chérrez-Ojeda, I. (2021). COVID-19 Vaccine-Associated Thrombosis with Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis. *Clin Appl Thromb Hemost*, 27:10760296211048815. <https://doi.org/10.1177/10760296211048815>

- Inserra, F., Tajer, C., Antonietti, L., Mariani, J., Ferder, L., & Manucha, W. (2021). Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2? *Vaccine*, 39(35): 4930-4931. <https://doi.org/10.1016/j.vaccine.2021.07.031>
- Ioannidis, J.P.A. (2020). Infection fatality rate of COVID-19 inferred from seroprevalence data. *Bulletin of the WHO*, 99(1): 19-33F. <https://doi.org/10.2471/BLT.20.265892>
- Iwasaki, A., & Yang, Y. (2020). The potential danger of suboptimal antibody responses in COVID-19. *Nat Rev Immunol*, 20(6): 339-341. <https://doi.org/10.1038/s41577-020-0321-6>
- Jackson, L.A., Anderson, E.J., Roupheal, N.G., Roberts, P.C., Makhene, M., Coler, R.N., McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., Pruijssers, A.J., McDermott, A., Flach, B., Doria-Rose, N.A., Corbett, K.S., Morabito, K.M., O'Dell, S., Schmidt, S.D., Swanson, P.A., Padilla, M., Mascola, J.R., Neuzil, K.M., Bennett, H., Sun, W., Peters, E., Makowski, M., Albert, J., Cross, K., Buchanan, W., Pikaart-Tautges, R., Ledgerwood, J.E., Graham, B.S., & Beigel, J.H. (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*, 2022483. <https://doi.org/10.1056/NEJMoa2022483>
- Janiaud, P., Hemkens, L.G., & Ioannidis, J.P.A. (2021). Challenges and lessons learned from COVID-19 trials - should we be doing clinical trials differently? *Can J Cardiol*, S0828-282X(21)00285-3. doi: 10.1016/j.cjca.2021.05.009
- Jenkins, H.E., Aylward, R.B., Gasasira, A., Donnelly, C.A., Mwanza, M., Corander, J., Garnier, S., Chauvin, C., Abanida, E., Pate, M.A., Adu, F., Baba, M., & Grassly, N.C. (2010). Implications of a circulating vaccine-derived poliovirus in Nigeria. *N Engl J Med*, 362(25): 2360-9. <https://doi.org/10.1056/NEJMoa0910074>
- Jiang, H., & Mei, Y.F. (2021). SARS-CoV-2 spike impairs DNA damage repair and inhibits V(D)J recombination *in vitro*. *Viruses*, 13(10):2056. <https://doi.org/10.3390/v13102056>
- Jiang, S. (2020). Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. *Nature*, 579: 321. <https://doi.org/10.1038/d41586-020-00751-9>
- Jones, N. (2020). How COVID-19 is changing the cold and flu season. *Nature*, 588(7838): 388-390. <https://doi.org/10.1038/d41586-020-03519-3>
- Kaur, U., Ojha, B., Pathak, B.K., Singh, A., Giri, K.R., Singh, A., Das, A., Misra, A., Yadav, A.K., Kansal, S., & Chakrabarti, S.S. (2021). A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. *E Clinical Medicine*, 38:101038. <https://doi.org/10.1016/j.eclinm.2021.101038>
- Keehner, J., Horton, L.E., Binkin, N.J., Laurent, L.C., Pride, D., Longhurst, C.A., Abeles, S.R., & Torriani, F.J. (2021). Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. *N Engl J Med*, 2021 ahead of print; <https://doi.org/10.1056/NEJMc2112981>
- Kennedy, R. F., Jr. (2021). *The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health*. Skyhorse Publishing (NY). ISBN 978-1-5107-6680-8
- Kim, D., Wu, Y., Shim, G., & Oh, Y.-K. (2021). Lipid nanoparticle-mediated lymphatic delivery of immunostimulatory nucleic acids. *Pharmaceutics*, 13(4), 490. <https://doi.org/10.3390/pharmaceutics13040490>
- Kim, M.A., Lee, Y.W., Kim, S.R., Kim, J.H., Min, T.K., Park, H.S., Shin, M., Ye, Y.M., Lee, S., Lee, J., Choi, J.H., Jang, G.C., & Chang, Y.S. (2021). COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. *Allergy Asthma Immunol Res*, 13(4):526-544. <https://doi.org/10.4168/aaair.2021.13.4.526>
- Kissling, E., Rose, A., Emborg, H.D., Gherasim, A., Pebody, R., Pozo, F., Trebbien, R., Mazagatos, C., Whitaker, H., Valenciano, M., European IVE group (2019). Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. *Euro Surveil*, 24(8): 1900121. <https://doi.org/10.2807/1560-7917.ES.2019.24.1900121>
- Kostoff, R.N., Calina, D., Kanduc, D., Briggs, M.B., Vlachoyiannopoulos, P., Svistunov, A.A., & Tsatsakis, A. (2021). Why are we vaccinating children against COVID-19? *Toxicol Rep*. 8: 1665-1684. <https://doi.org/10.1016/j.toxrep.2021.08.010>
- Kowarz, E., Krutzke, L., Reis, J., Bracharz, S., Kochanek, S., & Marschalek, R. (2021). Vaccine-induced COVID-19 mimicry” syndrome: splice reactions within the SARS-CoV-2 spike open reading frame result in spike protein variants that may cause

- thromboembolic events in patients immunized with vector-based vaccines. *Nature-portfolio* [preprint] <https://doi.org/10.21203/rs.3.rs-558954/v1>
- Krutzke, L., Roesler, R., Wiese, S., & Kochanek, S. (2021). Process-related impurities in the ChAdOx1 nCov-19 vaccine. *Nature-portfolio* [preprint] <https://doi.org/10.21203/rs.3.rs-477964/v1>
- Kucirka, L.M., Lauer, S.A., Laeyendecker, O., Boon, D., & Lessler, J. (2020). Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Ann Intern Med*, M20-1495. <https://doi.org/10.7326/M20-1495>
- Kulldorff, M., Gupta, S., & Bhattacharya, J. (2020) Great Barrington Declaration. <https://gbdeclaration.org/> (accessed: Feb. 2021)
- Lee, W.S., Wheatley, A.K., Kent, S.J DeKosky, B.J. (2020). Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol*, 5(10): 1185-1191. <https://doi.org/10.1038/s41564-020-00789-5>
- Lessells, R.J. (2021). SARS-CoV-2 variants of concern: the knowns and unknowns. *Anaesthesia Critical Care & Pain Medicine*, <https://doi.org/10.1016/j.accpm.2021.100868>
- Leslie, R. (2021). How COVID hurt the fight against other dangerous diseases. *Nature*, 592: 502-504. <https://doi.org/10.1038/d41586-021-01022-x>
- Lippi, G., Plebani, M., & Henry, B.M. (2020). Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*, 506:145-148. <https://doi.org/10.1016/j.cca.2020.03.022>
- Livny, A. (2021). The Testimonies Project — testimonies after Covid-19 vaccination. <https://www.vaxtestimonies.org/en/> (accessed: Sept. 2021)
- Liu, S., Wang, J., Liu, Y., Xu, Y., Che, X., Gu, W., Du, J., Zhang, X., & Xu, E. (2017). Survey of contraindications in children's routine vaccination in Hangzhou, China. *Hum Vacc Immunother*, 13(7):1539-1543. <https://doi.org/10.1080/21645515.2017.1304868>
- Loffredo, J. (2021). British Funeral Director Tells RFK, Jr. About Fear, Propaganda and COVID Vaccine Deaths During Early Days of Pandemic. *Children's Health Defense*. <https://childrenshealthdefense.org/defender/rfk-jr-podcast-john-oolooney-fear-propaganda-COVID-vaccine-deaths/> (accessed: Dec. 2021)
- Lopalco, P.L. (2017). Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. *Epidemiol Infect*, 145(3): 413-419. <https://doi.org/10.1017/S0950268816002569>
- Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P.A., Cuapio, A., & Villapol, S. (2021). More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *medRxiv* [preprint]: 2021.01.27.21250617. <https://doi.org/10.1101/2021.01.27.21250617>
- Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing COVID-19 vaccines at pandemic speed. *N Engl J Med*, 382:1969-1973; <https://doi.org/10.1056/NEJMp2005630>
- Lyons-Weiler, J. (2020). Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. *J Transl Autoim*, 3: 100051. <https://doi.org/10.1016/j.jtauto.2020.100051>
- Lyons-Weiler, J., McFarland, G., & La Joie, E. (2020). Impact of catch-up vaccination on aluminum exposure due to new laws and post social distancing. *J Trace Elem Med Biol*, 62:126649. <https://doi.org/10.1016/j.jtemb.2020.126649>
- Madl, P., Arvay, C., Gatti, A., Giuliani, L., Lettner, H. (2021). Air Pollution, SARS-CoV-2 and the Wider Implications - An Overview of Recent Events with a Focus on Italy. *Aerosol Air Qual. Res*, 21, 200438. <https://doi.org/10.4209/aaqr.200438>
- Mallapaty, S. (2021). COVID vaccines cut the risk of transmitting Delta - but not for long. *Nature*, <https://doi.org/10.1038/d41586-021-02689-y>
- Mansuriya, B.D., & Altintas, Z. (2021). carbon dots: classification, properties, synthesis, characterization, and applications in health care-an updated review (2018-2021). *Nanomaterials*, 11(10), 2525. <https://doi.org/10.3390/nano11102525>

- Masson, J.D., Crépeaux, G., Authier, F.J., Exley, C., & Gherardi, R.K. (2017). [Critical analysis of reference studies on aluminium-based adjuvants toxicokinetics]. *Annales Pharmaceutiques Françaises*, 75(4), 245–256. <https://doi.org/10.1016/j.pharma.2017.04.004>
- Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Ortiz-Ospina, E. (2021). A global database of COVID-19 vaccinations. *Nat Hum Behav* 5: 947-953. doi: 10.1038/s41562-021-01122-8; Data on COVID-19 (coronavirus) vaccinations by *Our World in Data*, accessible: <https://github.com/owid/COVID-19-data/tree/master/public/data/vaccinations>
- McCullough, P.A., Kelly, R.J., Ruocco, G., Lerma, E., Tumlin, J., Wheelan, K.R., Katz, N., Lepor, N.E., Vijay, K., Carter, H., Singh, B., McCullough, S.P., Bhambi, B.K., Palazzuoli, A., De Ferrari, G.M., Milligan, G.P., Safder, T., Tecson, K.M., Wang, D.D., McKinnon, J.E., O'Neill, W.W., Zervos, M., & Risch, H.A. (2021). Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) Infection. *Am J Med*, 134(1):16-22. <https://doi.org/10.1016/j.amjmed.2020.07.003>
- Menni, C., Klaser, K., May, A., Polidori, L., Nguzen, L.H., Drew, D.A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L.S., Molteni, E., Graham, M.S., Modat, M., Joshi, A.D., Mangino, M., Hammers, A., Goodman, A.L., Chan, A.T., Wolf, J., Steves, C.J., Valdes, A.M., Ourselin, S., & Spector, T.D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *Lancet Infect Dis*, 21(7): 939-949. [https://doi.org/10.1016/S1473-3099\(21\)00224-3](https://doi.org/10.1016/S1473-3099(21)00224-3)
- Mereckiene, J. (2018). Seasonal influenza vaccination and antiviral use in EU/EEA Member States. European Centre for Disease Prevention and Control. <https://doi.org/10.2900/721517> or <https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states>
- Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E.J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M.S., Keinan-Boker, L., & Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against COVID-19 in Israel. *N Engl J Med*, NEJMoa2109730. <https://doi.org/10.1056/NEJMoa2109730>
- MWGFED, (2021). Mediziner und Wissenschaftler fuer Gesundheit, Freiheit und Demokratie e.V (Association of Physicians and Scientists for Health, Freedom and Democracy). <https://www.mwgfd.de/> (accessed: Dec. 2021)
- Miller, M.B., & Bassler, B.L. (2001). Quorum sensing in bacteria. *Annu Rev Microbiol*, 55: 165-99. <https://doi.org/10.1146/annurev.micro.55.1.165>
- Moelling, K. (2017). *Viruses, More Friends Than Foes*. World Scientific, Singapore. ISBN 978-9-813-14782-9. https://doi.org/10.1142/9789813147836_0001
- Mold, M., Shardlow, E., & Exley, C. (2016). Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations. *Scientific Reports*, 6, 31578. <https://doi.org/10.1038/srep31578>
- Molina, V., & Shoenfeld, Y. (2005). Infection, vaccines and other environmental triggers of autoimmunity. *Autoimmunity*, 38(3):235-45. <https://doi.org/10.1080/08916930500050277>.
- Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., & Erlich, H. (1986). Specific Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction. *Cold Spring Harbor Symposia on Quantitative Biology*, 51, 263–273. <https://doi.org/10.1101/SQB.1986.051.01.032>
- Naito, Y., Takagi, T., Yamamoto, T., & Watanabe, S. (2020). Association between selective IgA deficiency and COVID-19. *J Clin Biochem Nutr*, 67(2): 122-125. <https://doi.org/10.3164/jcbn.20-102>
- Nair, M.S., Huang, Y., Fidock, D.A., Towler, M.J., & Weathers, P.J. (2021). *Artemisia annua* hot-water extracts show potent activity *in vitro* against Covid-19 variants including delta. *bioRxiv*, 2021.09.08.459260. <https://doi.org/10.1101/2021.09.08.459260>
- NatBiotech, (2016). Research not fit to print. *Nat Biotechnol*, 34(2): 115. <https://doi.org/10.1038/nbt.3488>. PMID: 26849496
- Negro, F. (2020). Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? *Swiss Med Wkly*, 150: w20249. <https://doi.org/10.4414/smw.2020.20249>
- Nelde, A., Bilich, T., Heitmann, J.S., Maringer, Y., Salih, H.R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., Traenkle, B., Kaiser, P.D., Rothbauer, U., Becker, M., Junker, D., Krause, G., Strengert, M., Schneiderhan-Marra,

- N., Templin, M.F., Joos, T.O., Kowalewski, D.J., Stos-Zweifel, V., Fehr, M., Rabsteyn, A., Mirakaj, V., Karbach, J., Jäger, E., Graf, M., Gruber, L.C., Rachfalski, D., Preuss, B., Hagelstein, I., Märklin, M., Bakchoul, T., Gouttefangeas, C., Kohlbacher, O., Klein, R., Stevanović, S., Rammensee, H.G., & Walz, J.S. (2021). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nat Immunol*, 22(1):74-85. <https://doi.org/10.1038/s41590-020-00808-x>
- Ng, W.H., Liu, X., & Mahalingam, S. (2020). Development of vaccines for SARS-CoV-2. F1000 Faculty Rev-991. <https://doi.org/10.12688/f1000research.25998.1>
- Nicolas, E.S. (2021). Advice on AstraZeneca varies across EU, amid blood clot fears. EuObserver. <https://euobserver.com/coronavirus/151485> (accessed: Feb. 2021)
- Niesen, M.J.M., Anand, P., Silvert, E., Suratekar, R., Pawlowski, C., Ghosh, P., Lenehan, P., Hughes, T., Zemmour, D., O'Horo, J.C., Yao, J.D., Pritt, B.S., Norgan, A., Hurt, R.T., Badley, A.D., Venkatakrisnan, A.J., & Soundararajan, V. (2021). COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance. *medRxiv*, 2021.07.01.21259833. <https://doi.org/10.1101/2021.07.01.21259833>
- Oller, J. W., & Shaw, C.A. (2019). From superficial damage to invasion of the nucleosome: Ranking of morbidities by the biosemiotic depth hypothesis. *International Journal of Sciences*, 8(06), 51–73. <https://doi.org/10.18483/ijSci.2069>
- Olliaro, P., Torreele, E., & Vaillant, M. (2021). COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. *Lancet Microbe*, 2(7): e279-e280. [https://doi.org/10.1016/S2666-5247\(21\)00069-0](https://doi.org/10.1016/S2666-5247(21)00069-0)
- Olszak, T., An, D., Zeissig, S., Vera, M.P., Richter, J., Franke, A., Glickman, J.N., Siebert, R., Baron, R.M., Kasper, D.L., & Blumberg, R.S. (2012). Microbial exposure during early life has persistent effects on natural killer T cell function. *Science*, 336(6080), 489–493. <https://doi.org/10.1126/science.1219328>
- Ou, J., Zhou, Z., Dai, R., Zhang, J., Zhao, S., Wu, X., Lan, W., Ren, Y., Cui, L., Lan, Q., Lu, L., Seto, D., Chodosh, J., Wu, J., Zhang, G., & Zhang, Q. (2021). V367F Mutation in SARS-CoV-2 Spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. *Journal of Virology*, 95(16), e00617-21. <https://doi.org/10.1128/JVI.00617-21>
- Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R. C., Zella, D., & Ippodrino, R. (2020). Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *Journal of Translational Medicine*, 18(1), 179. <https://doi.org/10.1186/s12967-020-02344-6>
- Palmieri, V., Perini, G., De Spirito, M., & Papi, M. (2019). Graphene oxide touches blood: in vivo interactions of bio-coronated 2D materials. *Nanoscale Horiz*, 4(2):273-290. <https://doi.org/10.1039/c8nh00318a>
- Petrik, M. S., Wong, M. C., Tabata, R. C., Garry, R. F., & Shaw, C. A. (2007). Aluminum adjuvant linked to Gulf War Illness induces motor neuron death in mice. *NeuroMolecular Medicine*, 9(1), 83–100. <https://doi.org/10.1385/NMM:9:1:83>
- PGEI, (2021). Circulating vaccine-derived poliovirus. Polio Global Eradication Initiative, WHO. <https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/> (accessed: April 2021)
- Pujol, A., Gomez, L.-A., Gallegos, C., Nicolau, J., Sanchis, P., Gonzalez-Freire, M., Lopez-Gonzalez, A. A., Dotres, K., & Masmiquel, L. (2021). Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: From Graves' disease to silent thyroiditis. *Journal of Endocrinological Investigation*. <https://doi.org/10.1007/s40618-021-01707-0>
- Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock, T., Robertson, D.L., Volz, E., COVID-19 Genomics Consortium UK (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563> (accessed: Feb. 2021)
- Raveendran, A.V., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: An overview. *Diabetes & Metabolic Syndrome*, 15(3), 869–875. <https://doi.org/10.1016/j.dsx.2021.04.007>
- Reiss, K., & Bhakdi, S. (2020). Corona False Alarm? Facts and Figures, 1st ed. Chelsea Green Publishing. ISBN: 978-1645020578

- Rose, J., & McCullough, P.A. (2021) A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products. *Curr Probl Cardiol*, 101011 ahead of print. <https://doi.org/10.1016/j.cpcardiol.2021.101011>
- Rosenthal, S., & Cummings, C.L. (2021). Influence of rapid COVID-19 vaccine development on vaccine hesitancy. *Vaccine*, S0264-410X(21)01448-1. <https://doi.org/10.1016/j.vaccine.2021.11.014>
- Salah, H.M., & Mehta, J.L. (2021). COVID-19 vaccine and myocarditis. *Am J Cardiol*, S0002-9149(21)00639-1. <https://doi.org/10.1016/j.amjcard.2021.07.009>
- Salle, V. (2021). Coronavirus-induced autoimmunity. *Clin Immunol*, 226:108694. <https://doi.org/10.1016/j.clim.2021.108694>
- Sander, V.A., Corigliano, M.G., & Clemente, M. (2019). Promising plant-derived adjuvants in the development of coccidial vaccines. *Front Vet Sci*, 6:20. <https://doi.org/10.3389/fvets.2019.00020>
- Shoenfeld, Y., & Aron-Maor, A. (2000). Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? *J Autoimmun*, 14(1):1-14. <https://doi.org/10.1006/jaut.1999.0346>
- Schuchat, A. (2021). Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. Center of Disease Control & Prevention. <https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html> (accessed: Feb. 2021)
- Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., Wullimann, D.J., Kammann, T., Emgård, J., Parrot, T., Folkesson, E., Karolinska COVID-19 Study Group, Rooyackers, O., Eriksson, L.I., Henter, J.I., Sönnnerborg, A., Allander, T., Albert, J., Nielsen, M., Klingström, J., Gredmark-Russ, S., Björkström, N.K., Sandberg, J.K., Price, D.A., Ljunggren, H.G., Aleman, S., & Buggert, M. (2020). Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell*, 183(1):158-168.e14. <https://doi.org/10.1016/j.cell.2020.08.017>
- Seneff, S., Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. *International Journal of Vaccine Theory, Practice, and Research*, 2(1): 38-79. Retrieved from <https://ijvtp.com/index.php/IJVTPr/article/view/23>
- Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K.J.A., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Galao, R.P., Betancor, G., Wilson, H.D., Signell, A.W., Winstone, H., Kerridge, C., Temperton, N., Snell, L., Bisnauthsing, K., Moore, A., Green, A., Martinez, L., Stokes, B., Honey, J., Izquierdo-Barras, A., Arbane, G., Pate, A., O'Connell, L., O'Hara, G., MacMahon, E., Douthwaite, S., Nebbia, G., Batra, R., Martinez-Nunez, R., Edgeworth, J.D., Neil, S.J.D., Malim, M.H., & Doores, K.J. (2020). Longitudinal evaluation and decline of antibody responses in 1 SARS-CoV-2 infection. *medRxiv*, 2020.07.09.20148429. <https://doi.org/10.1101/2020.07.09.20148429>
- Shao, S.C., Wang, C.H., Chang, K.C., Hung, M.J., Chen, H.Y., & Liao, S.C. (2021). Guillain-Barré Syndrome Associated with COVID-19 Vaccination. *Emerg Infect Dis*, 27(12): 3175-3178. <https://doi.org/10.3201/eid2712.211634>
- Shaw, C.A., Li, D., & Tomljenovic, L. (2014). Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy? *Immunotherapy*, 6(10), 1055–1071. <https://doi.org/10.2217/imt.14.81>
- Shaw, C. A., Seneff, S., Kette, S. D., Tomljenovic, L., Oller, J. W., & Davidson, R. M. (2014). Aluminum-induced entropy in biological systems: Implications for neurological disease. *Journal of Toxicology*, 491316. <https://doi.org/10.1155/2014/491316>
- Shi, Z., & Puyo, C.A. (2020). Acetylcysteine to Combat COVID-19: An evidence review. *Ther Clin Risk Manag*, 16: 1047-1055. <https://doi.org/10.2147/TCRM.S273700>
- Shimoyama, S., Kanisawa, Y., Ono, K., Souri, M., & Ichinose, A. (2021). First and fatal case of autoimmune acquired factor XIII/13 deficiency after COVID-19/SARS-CoV-2 vaccination. *Am J Hematol*, 1–3. <https://doi.org/10.1002/ajh.26426>
- Singh, J.A., & Upshur, R.E.G. (2020). The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. *Lancet Infect Dis*, 8: S1473-3099(20)30923-3. [https://doi.org/10.1016/S1473-3099\(20\)30923-3](https://doi.org/10.1016/S1473-3099(20)30923-3)
- South, A.M., Diz, D., & Chappell, M.C. (2020). COVID-19, ACE2, and the cardiovascular consequences. *American Journal of Physiology-Heart and Circulatory Physiology*, 318(5), H1084–H1090. <https://doi.org/10.1152/ajpheart.00217.2020>
- Stecklow, S., & Macaskill, A. (2021). The ex-Pfizer scientist who became an anti-vax hero. Reuters Special Report. <https://www.reuters.com/investigates/special-report/health-coronavirus-vaccines-skeptical/> (accessed: Dec. 2021)

- Sumi, T., Nagahisa, Y., Matsuura, K., Sekikawa, M., Yamada, Y., Nakata, H., & Chiba, H. (2021). Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech). *Thorax Cancer*, 12: 3072-3075. <https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.14179>
- SWPRS, (2021). On the Treatment of COVID-19. Swiss Policy Research Report. <https://swprs.org/on-the-treatment-of-COVID-19/> (accessed: Aug. 2021)
- Tablizo, F.A., Kim, K.M., Lapid, C.M., Castro, M.J.R., Yangzon, M.S.L., Maralit, B.A., Ayes, M.E.C., Cutiongco-de la Paz, E.M., De Guzman, A.R., Yap, J.M.C., Llamas, J.S., Araiza, S.M.M., Punayan, K.P., Asin, I.C.A., Tambaogan, C.F.B., Chong, A.L.U., Padilla, K.S.A.R., Cruz, R.P.S., Morado, E.K.D., Dizon, J.G.A., Hao, R.N.M., Zamora, A.A., Pacial, D.R., Magalang, J.A.R., Alejandria, M., Carlos, C., Ong-Lim, A., Salvaña, E.M., Wong, J.Q., Montoya, J.C., Singh-Vergeire, M.R., & Saloma, C.P. (2021). Genome sequencing and analysis of an emergent SARS-CoV-2 variant characterized by multiple spike protein mutations detected from the Central Visayas Region of the Philippines. *medRxiv*, 2021. <https://doi.org/10.1101/2021.03.03.21252812>
- Takano, T., Yamada, S., Doki, T., & Hohdatsu, T. (2019). Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route. *J Vet Med Sci*, 81(6): 911-915. <https://doi.org/10.1292/jvms.18-0702>
- TSC, (2021). Nanotechnological investigations on Covid-19 vaccines. White paper on “vaccines” compositions. The Scientists’ Club. (accessed: Aug. 2021) <https://secureservercdn.net/166.62.104.68/19t.39f.myftpupload.com/wp-content/uploads/2021/09/210819-SCIENTISTS-CLUB-ANALYSIS.pdf>
- Tomljenovic, L., & Shaw, C.A. (2011). Aluminum vaccine adjuvants: Are they safe? *Current Medicinal Chemistry*, 18(17): 2630–2637. <https://doi.org/10.2174/092986711795933740>
- Toussiro, É., & Bereau, M. (2015). Vaccination and Induction of Autoimmune Diseases. *Inflamm Allergy Drug Targets*. 2015;14(2):94-8. <https://doi.org/10.2174/1871528114666160105113046>.
- Tsumiyama, K., Miyazaki, Y., & Shiozawa, S. (2009). Self-organized criticality theory of autoimmunity. *PLoS One*, 4(12): e8382. <https://doi.org/10.1371/journal.pone.0008382>
- Turner, J.S., Kim, W., Kalaidina, E., Goss, C.W., Rauseo, A.M., Schmitz, A.J., Hansen, L., Haile, A., Klebert, M.K., Pusic, I., O'Halloran, J.A., Presti, R.M., & Ellebedy, A.H. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature*, 595: 421-525. <https://doi.org/10.1038/s41586-021-03647-4>
- Ura, T., Okuda, K., & Shimada, M. (2014). Development in viral vector based vaccines. *Vaccines*, 2(3): 624–641; <https://doi.org/10.3390/vaccines2030624>
- Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.A., Kaneda, A., The Genotype to Phenotype Japan (G2P-Japan) Consortium, Nakagawa, S., & Sato, K. (2021). Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. *bioRxiv*, 2021.09.06.459005. <https://doi.org/10.1101/2021.09.06.459005>
- VAERS, (2021). Searching the VEARS database. Vaccine Adverse Event Reporting System. <https://medalerts.org/vaersdb/index.php> (accessed: Feb. 2021); <https://openvaers.com/COVID-data/mortality> (accessed: Jan. 2022)
- Van Den Bossche, G. (2021). Why should current Covid-19 vaccines not be used for mass vaccination during a pandemic? Vaccines Summit Ohio 2021 (SOHI021). <https://www.geertvandenbossche.org/> (accessed: March 2021)
- Villarreal L.P., (2005) Viruses and the Evolution of Life. American Society for Microbiology Press, Washington (DC); ISBN 1-55581-309-7
- Villarreal, L.P., Witzany, G. (2013) Rethinking quasispecies theory: From fittest type to cooperative consortia. *World J Biol Chem*, 4(4): 79-90. <https://doi.org/10.4331/wjbc.v4.i4.79>
- Villarreal, L.P. (2015) Virolution Can Help Us Understand the Origin of Life. In: Kolb V (ed). *Astrobiology – An Evolutionary Approach*. CRC Press, Boca Raton (FL); ISBN 13-978-1-4665-8462-4
- Villarreal, L.P., Witzany, G. (2021) Social networking of quasi-species consortia drive virolution via persistence. *AIMS Microbiology*, 7(2): 138-162. <https://doi.org/10.3934/microbiol.2021010>

- Vojdani, A., Vojdani, E., & Kharrazian, D. (2021). Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. *Front Immunol*, 11:617089. <https://doi.org/10.3389/fimmu.2020.617089>
- Wadman, M. (2021). Israel's grim warning: Delta can overwhelm shots. *Science*, 373(6557): 838-839. <https://doi.org/10.1126/science.acx8926>
- Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., Hussain, S., Nicod, J., Goldstone, R., Ambrose, K., Hindmarsh, S., Beale, R., Riddell, A., Gamblin, S., Howell, M., Kassiotis, G., Libri, V., Williams, B., Swanton, C., Gandhi, S., & Bauer, D.L. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet*, 19;397(10292): 2331-2333. [https://doi.org/10.1016/S0140-6736\(21\)01290-3](https://doi.org/10.1016/S0140-6736(21)01290-3).
- Wallukat, G., Hohberger, B., Wenzel, K., Fürst, J., Schulze-Rothe, S., Wallukat, A., Hönicke, A.S., & Müller, J. (2021). Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. *J Transl Autoimmun*, 4: 100100. <https://doi.org/10.1016/j.jtauto.2021.100100>
- Wang, J., Lu, L., Song, H., Yang, Y., & Ma, Y. (2010). [Effect of polyethylene glycol as adjuvant on hepatitis B virus DNA vaccine in vitro]. *Wei Sheng Wu Xue Bao = Acta Microbiologica Sinica*, 50(7), 949–954. <https://pubmed.ncbi.nlm.nih.gov/20815244/>
- Waters, C.M., & Bassler, B.L. (2005). Quorum sensing: cell-to-cell communication in bacteria. *Annu Rev Cell Dev Bio*, 21: 319-46. <https://doi.org/10.1146/annurev.cellbio.21.012704.131001>
- Watson, J., Whiting, P.F., & Brush, J.E. (2020). Interpreting a covid-19 test result. *BMJ*, 369: m1808. <https://doi.org/10.1136/bmj.m1808>
- White, D.O., & Fenner, F.J. (1994) Medical Virology, 4th ed. Academic Press, San Diego (CA). ISBN 0-12-746642-8
- WHO, (2021). COVID-19 Vaccine AstraZeneca solution for injection. https://extranet.who.int/pqweb/sites/default/files/documents/WHO_PL_azd1222.pdf (accessed: Feb. 2021)
- Wilson, A. (2021). Dr. Ryan Cole Shares 20-fold Increase of Cancers & Autoimmune Diseases in Vaccinated Population. *The True Defender!* <https://thetruede defender.com/dr-ryan-cole-shares-20x-increase-of-cancers-autoimmune-diseases-in-vaccinated-population/> or alternatively: <https://vaccinesafety.info/2021/08/26/dr-ryan-cole-stopthemandate/> (accessed: Sep. 2021)
- Win-Shwe, T.T., & Fujimaki, H. (2011). Nanoparticles and neurotoxicity. *Int J Mol Sci*, 12(9): 6267-6280; <https://doi.org/10.3390/ijms12096267>
- Wise, J. (2021). Covid-19: The E484K mutation and the risks it poses. *BMJ*, 372: n359. <https://doi.org/10.1136/bmj.n359>
- Witzany, G. (2006). Natural Genome-Editing Competences of Viruses. *Acta Biotheoretica*, 54: 235-253. <https://doi.org/10.1007/s10441-007-9000-7>
- Wodarg, W.(2021). Viren sind nicht das Problem - bleiben Sie besonnen! (Viruses are not the problem - stay calm!). <https://www.wodarg.com/about/> (accessed: Dec. 2021)
- Wolff, G. (2020). Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017–2018 influenza season. *Vaccine*, 38: 350–354. <https://doi.org/10.1016/j.vaccine.2019.10.005>
- Wood, D., Pereyra, M., Halfon, N., Hamlin, J., & Grabowsky, M. (1995). Vaccination levels in Los Angeles public health centers: the contribution of missed opportunities to vaccinate and other factors. *Am J Public Health*, 85(6): 850-853. <https://doi.org/10.2105/ajph.85.6.850>
- Wraith, D.C., Goldman, M., & Lambert, P.H. (2003). Vaccination and autoimmune disease: what is the evidence? *Lancet*, 15;362(9396):1659-1666. [https://doi.org/10.1016/S0140-6736\(03\)14802-7](https://doi.org/10.1016/S0140-6736(03)14802-7).
- Xu, L., Xiang, J., Liu, Y., Xu, J., Luo, Y., Feng, L., Liu, Z., & Peng, R. (2016). Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity. *Nanoscale*, 14;8(6):3785-95. <https://doi.org/10.1039/c5nr09208f>.
- Xu, L., Ma, Z., Li, Y., Pang, Z., & Xiao, S. (2021). Antibody dependent enhancement: Unavoidable problems in vaccine development. *Adv Immunol*, 151:99-133. <https://doi.org/10.1016/bs.ai.2021.08.003>

- Xu, N., Gu, Q., Du, J., Ge, H., Long, S., Sun, W., Fan, J., & Peng, X. (2021). Photodynamic inheritance from methylene blue to carbon dots against reduction, aggregation, and DNA interference. *Science China-Materials*, 64(9), 2325–2336. <https://doi.org/10.1007/s40843-020-1623-4>
- Yan, B., Chakravorty, S., Mirabelli, C., Wang, L., Trujillo-Ochoa, J.L., Chauss, D., Kumar, D., Lionakis, M.S., Olson, M.R., Wobus, C.E., Afzali, B., & Kazemian, M. (2021). Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and artifactual. *BioRxiv*, [preprint]: 2021.02.17.431704. <https://doi.org/10.1101/2021.02.17.431704>
- Zhang, L.Z., Jackson, C.B., Mou, H.H., Ojha, A., Rangarajan, E.S., Izard, T., Farzan, M., & Choe, H.Y. (2020a). The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. Scripps Research preprint. <https://www.scripps.edu/news-and-events/press-room/2020/20200611-choe-farzan-sars-cov-2-spike-protein.html> (accessed: June 2020).
- Zhang, L., Richards, A., Khalil, A., Wogram, E., Ma, H., Young, R.A., & Jaenisch, R. (2020b). SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. *bioRxiv*, [preprint]: 2020.12.12.422516. <https://doi.org/10.1101/2020.12.12.422516>
- Zhang, S., Liu, Y., Wang, X., Yang, L., Li, H., Wang, Y., Liu, M., Zhao, X., Xie, Y., Yang, Y., Zhang, S., Fan, Z., Dong, J., Yuan, Z., Ding, Z., Zhang, Y., & Hu, L. (2020c). SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol*, 13(1): 120. <https://doi.org/10.1186/s13045-020-00954-7>
- Zhang, H., & Xia, X. (2021). RNA cancer vaccines: Developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy. *Human Vaccines & Immunotherapeutics*, 17(9), 2995–2998. <https://doi.org/10.1080/21645515.2021.1921524>
- Zhang, L., Richards, A., Barrasa, M.I., Hughes, S.H., Young, R.A., Jaenisch, R. (2021). Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. *PNAS*, 118 (21), e2105968118. <https://doi.org/10.1073/pnas.2105968118>

Legal Disclaimer

The information on the website and in the *IJVTPR* is not intended as a diagnosis, recommended treatment, prevention, or cure for any human condition or medical procedure that may be referred to in any way. Users and readers who may be parents, guardians, caregivers, clinicians, or relatives of persons impacted by any of the morbid conditions, procedures, or protocols that may be referred to, must use their own judgment concerning specific applications. The contributing authors, editors, and persons associated in any capacity with the website and/or with the journal disclaim any liability or responsibility to any person or entity for any harm, financial loss, physical injury, or other penalty that may stem from any use or application in any context of information, conclusions, research findings, opinions, errors, or any statements found on the website or in the *IJVTPR*. The material presented is freely offered to all users who may take an interest in examining it, but how they may choose to apply any part of it, is the sole responsibility of the viewer/user. If material is quoted or reprinted, users are asked to give credit to the source/author and to conform to the non-commercial, no derivatives, requirements of the [Creative Commons License 4.0 NC ND](https://creativecommons.org/licenses/by-nc-nd/4.0/).